The QualityStocks Daily Wednesday, September 16th, 2020

Today's Top 3 Investment Newsletters

QualityStocks (BLGI) +85.38%

StocksToBuyNow (GRYN) +49.98%

MarketClub Analysis (ARWR) +40.33%

The QualityStocks Daily Stock List

Better Plant Sciences, Inc. (VEGGF)

FX Empire, Newsfilecorp, MarketWatch, Nasdaq, GuruFocus, Shroom Investor, Financhill, Stockwatch, Seeking Alpha, InvestorsHub, Business Wire, Bloomberg, Stockhouse, Wallmine, Baystreet.ca, Dividend.com, CNSX Markets, Newslookup, Grassnews, The CES, Psychedelic Invest, Investing.com, TradingView, TipRanks, and Market Screener reported earlier on Better Plant Sciences, Inc. (VEGGF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Better Plant Sciences, Inc. develops and acquires intellectual property (IP) and other assets related to plant-based products and therapeutics. By way of its integrated business model, the Company develops, manufactures, markets, sells, and distributes plant-based products. The Company’s majority-owned subsidiary is NeonMind Biosciences, Inc. A vertically-integrated company, Better Plant Sciences has its corporate headquarters in Vancouver, British Columbia.

The Company has 14 patent applications to protect its IP. In addition, it has more than 200 proprietary wellness formulas at different stages of commercialization. This includes greater than 20 proprietary products that are now for sale through eCommerce or brick-and-mortar retail stores.

Better Plant Sciences operates websites and oversees eCommerce and Amazon sales for more than 200 JUSU plant based products for body, baby, and also home. The Company’s NeonMind Biosciences subsidiary is launching a line of coffees infused with health optimizing medicinal mushrooms. This includes reishi, cordyceps, lion's mane, as well as turkey tail mushrooms.

Moreover, NeonMind Biosciences also involves in research into developing a psilocybin (psychedelic mushroom) based product for weight loss. It has applied for a Section 56 Exemption to commence preclinical trials to study its pending psychedelic medicine patents.

Better Plant Sciences’ all natural products vary in use from pain treatment to disease prevention to health optimization. These are all without chemicals or harmful ingredients. In essence, The Company creates formulations with the highest quality, natural raw ingredients. It combines modern science with nature to create highly-effective, results-driven products for the mind, body, and home.

Better Plant Sciences’ brands include Urban Juve skincare products. Its brands also include its above-mentioned NeonMind branded products. Furthermore, its brands include Wright & Well. Its Wright & Well THC creates THC (Tetrahydrocannabinol)-infused topicals for health-conscious customers looking for alternative ways to improve their wellbeing. Wright & Well formulations sell through Oregon dispensaries.

Additionally, Wright & Well CBD produces potent topicals infused with the non-psychoactive healing potential of cannabis. Wright & Well CBD will bring premier CBD(cannabidiol)-infused products to the California marketplace. Better Plant Sciences also has its Jack & Jane brand. Jack & Jane has a high-quality line of THC and CBD-infused products. This includes tinctures, topicals, as well as capsules.

Another Company brand is W&W Manufacturing. W&W offers consumer skincare and wellness products infused with Cannabidiol (CBD). Also, Better Plant Sciences has its UJ Beverages brand. It has purchased wellness beverage formulas designed to be infused with CBD and THC. Moreover, the Company’s Thrive Activations, Inc. provides management personnel, technology, and marketing strategies, and also business incubation services to growing companies.

Last week, Better Plant Sciences announced that subsidiary Urban Juve completed manufacturing of its hand sanitizer gel. It is launching the product in the United States and Canada. The hand sanitizer gel is listed with the FDA (Food and Drug Administration) (NDC 75385-0010-1). It has received Natural health Product Number 80098154 from Health Canada. Urban Juve's Ultra Hydrating Hand Sanitizer Spray received Health Canada approval on March 27, 2020 (NPN 80097926).

Better Plant Sciences, Inc. (VEGGF), closed Wednesday's trading session at $0.060192, up 2.3673%, on 137,407 volume with 26 trades. The stock's 52-week low/high is $0.050700001/$0.300999999.

BriaCell Therapeutics Corp. (BCTXF)

NetworkNewsWire, Stock Day Media, Zacks, Small Cap Voice, Financhill, Investing News, Morningstar, YCharts, docoh, GuruFocus, Stock News Now, Proactive Investors, Barchart, TMXmoney, MarketWatch, Seeking Alpha, Business Insider, Stockhouse, Nasdaq, Stocks to Buy Now, Street Insider, GlobeNewswire, Wall Street Analyzer, CRWE World, InvestorsHub, CEO.ca, MacroTrends, and OTC Markets reported previously on BriaCell Therapeutics Corp. (BCTXF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, BriaCell Therapeutics Corp. is a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer. Its commitment is to enhancing the lives of women who are facing limited breast cancer therapy options. The Company’s mission has been to develop novel immunotherapies to fight cancer. Incorporated in 2006, BriaCell Therapeutics has its Canadian corporate office in West Vancouver, British Columbia. Its U.S. corporate office is in Berkeley, California.

Bria-IMT™ (SV-BR-1-GM) was designed by the Company’s team of scientists and clinicians. BriaCell’s proprietary whole-cell based technology platform continues to show its potential for treating breast cancer patients. The Company’s lead product candidate is Bria-IMT™. It has been shown to stimulate components of the immune system in advanced breast cancer patients. BriaCell maintains rights for Bria-IMT™.

Concerning Bria-IMT™ Monotherapy, in a preliminary Phase I clinical study in advanced breast cancer patients who had failed numerous treatments, treatment with Bria-IMT™ substantially reduced tumor size, without serious side effects. Regression of breast cancer was observed in other sites including the lung and the brain. The median lifespan of the patients was considerably longer than anticipated in these advanced breast cancer patients.

BriaCell Therapeutics currently has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates. With this agreement, Incyte and BriaCell will be evaluating novel combinations of compounds from Incyte’s development portfolio with BriaCell’s drug candidates in advanced breast cancer patients.

Also, pertaining to a combination Study of Bria-IMT™ with KEYTRUDA®, BriaCell Therapeutics earlier announced a Grant to Investigator, Dr. Saveri Bhattacharya, at Sidney Kimmel Cancer Center – Jefferson Health for a Phase I/IIa Combination Study of Bria-IMT™ with KEYTRUDA® (manufactured by Merck & Co., Inc. (NYSE: MRK)) in advanced breast cancer.

Moreover, BriaCell is developing Bria-OTS™. This is the first “off the shelf” personalized immunotherapy for the treatment for advanced stage breast cancer. Additionally, the Company’s small molecule program consists of novel, selective protein kinase C delta inhibitors, which have shown activity in pre-clinical models of several cancers and fibrotic diseases.

Earlier this month, BriaCell Therapeutics announced that it received a research grant from the Wiseman Cancer Research Foundation, a 501c(3) non-profit organization headquartered in Beverly Hills, California. The research grants are awarded to individual scientists or entities that pursue outstanding research in immuno-oncology. Dr. Charles L. Wiseman, BriaCell Therapeutics’ Scientific Founder and Director, presently serves as President of the Wiseman Cancer Research Foundation.

BriaCell Therapeutics Corp. (BCTXF), closed Wednesday's trading session at $4.84, even for the day, on 10 volume with 1 trades. The average volume for the last 3 months is 536 and the stock's 52-week low/high is $0.022454999/$20.3600006.

Cellectar Biosciences, Inc. (CLRB)

NetworkNewsWire, Stocktwits, BioPharmCatalyst, Investor Deck, Zacks, BioPharmaJournal, Invest Million, MacroTrends, Invest Chronicle, GuruFocus, Investors Observer, Morningstar, MarketWatch, GlobeNewswire, Barchart, Business Insider, Finviz, last10k, Simply Wall St, Fintel, Market Screener, TMXmoney, Stockhouse, StockNews, DBT News, Investing.com, Barron’s, InvestorsHub, Seeking Alpha, Nasdaq, and MarketBeat reported earlier on Cellectar Biosciences, Inc. (CLRB), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

A clinical-stage biopharmaceutical company, Cellectar Biosciences, Inc. concentrates on the discovery, development, and commercialization of drugs for the treatment of cancer. It is developing proprietary drugs independently and through research and development (R&D) collaborations. Its core goal is to take advantage of its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety because of fewer off-target effects.

The Company previously went by the name Novelos Therapeutics, Inc. It changed its corporate name to Cellectar Biosciences, Inc. in February of 2014. Established in 2002, Cellectar Biosciences is based in Florham Park, New Jersey. The Company’s shares trade on the NasdaqGS.

Cellectar’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments. The Company’s product pipeline includes one preclinical PDC chemotherapeutic program (CLR 1900) and numerous partnered PDC assets.

The Company’s lead PDC therapeutic, CLR 131, is presently in two clinical studies. The CLOVER-1 Phase 2 study completed the Part A dose-exploration portion, conducted in relapsed/refractory (r/r) B-cell malignancies. It is currently enrolling in the Part B expansion cohorts evaluating a two cycle dosing regimen, which provides roughly 100 mCi total body dose of CLR 131 in r/r multiple myeloma (MM) and lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia (LPL/WM).

The Phase 1 pediatric study is an open-label, sequential-group, dose-escalation study to evaluate the safety and tolerability of CLR 131 in children and adolescents with relapsed or refractory cancers. These include malignant brain tumors, neuroblastoma, sarcomas, as well as lymphomas (including Hodgkin’s lymphoma). The Phase 1 study is being conducted worldwide at seven top pediatric cancer centers.

Last week, Cellectar Biosciences announced that a clinically meaningful 40 percent overall response rate (ORR) was observed in the subset of refractory multiple myeloma patients deemed triple class refractory who received a total administered dose of 60 mCi or greater. Triple class refractory is defined as patients refractory to immunomodulatory, proteasome inhibitors, and also anti-CD38 antibody drug classes.

Dr. John Friend, CMO of Cellectar Biosciences, said, “We remain encouraged by the consistency of CLR 131’s efficacy and tolerability data in these extremely challenging to treat triple class refractory multiple myeloma patients. A 40% ORR is a clinically meaningful outcome. For reference purposes, two recently approved drugs received a 25% and 31% ORR in triple class refractory patients. We look forward to the further development of CLR 131, a first in class phospholipid radio conjugate that may provide a significant benefit to patients and treatment alternative for clinicians."

Cellectar Biosciences, Inc. (CLRB), closed Wednesday's trading session at $1.22, off by 1.6129%, on 321,839 volume with 763 trades. The average volume for the last 3 months is 904,325 and the stock's 52-week low/high is $1.00999999/$3.32999992.

Kindred Biosciences, Inc. (KIN)

NetworkNewsWire, Zacks, KnowTheStock, Stocktwits, Stockhouse, StreetWise Reports, MacroTrends, Simply Wall St, CEO.ca, InvestorsHub, FX Empire, EarningsCast, Equity Clock, last10k, Equities.com, Morningstar, Finviz, EarningsCast, Market Screener, Wallet Investor, Stockopedia, TMXmoney, Stocknews, Marketing Sentinel, Stockwatch, YCharts, Seeking Alpha, Nasdaq, Proactive Investors, and GuruFocus reported beforehand on Kindred Biosciences, Inc. (KIN), and today we report on the Company, here at the QualityStocks Daily Newsletter.

A biopharmaceutical company, Kindred Biosciences, Inc. centers on saving and improving the lives of pets. Its mission is to bring inventive biologics to veterinary medicine. Its core strategy is to identify targets that have already been proven safe and effective in humans. The Company’s expertise is in the development of biologics: monoclonal antibodies and recombinant proteins.

Kindred Biosciences has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a wide-ranging intellectual property (IP) portfolio. Kindred Biosciences lists on the NasdaqGS. The Company is based in Burlingame, California.

The Company has unique biologics in development specifically for dogs, their owners, and the veterinarians that care for them. Kindred is taking a multi-pronged approach toward atopic dermatitis. This the leading reason owners take their dog to the veterinarian. In addition, the Company is developing product candidates to address parvovirus and inflammatory bowel disease in dogs.

Kindred Biosciences is also a front runner in developing innovative new treatments in feline medicine. Its feline pipeline includes “Non-regenerative Anemia in Cats-KIND-510a”. Anemia has been associated with progression in feline chronic kidney disease, and potentially contributes to renal hypoxia, and also reduced energy and appetite (Jessica Quimby, DVM, Ph.D., DACVIM).

This past June, Kindred Biosciences announced a plan to enhance its strategic position. It will prioritize its most attractive late stage programs and considerably lessen expenses to best position it for success with the earlier announced business model.

The Company’s intention is to decrease operating expenditures through prioritizing investment in its highest value, late stage programs, especially the interleukin-31 (IL-31) antibody, interleukin-4 receptor (IL-4R) antibody, and parvovirus antibody programs. These actions, alongside a streamlining of its operations, are expected to decrease quarterly operating expenses to roughly $10 million by Q4 of 2020 and maintain expenditures at a similar level through 2021.

Kindred Biosciences, Inc. (KIN), closed Wednesday's trading session at $5.08, up 10.6754%, on 687,581 volume with 4,750 trades. The average volume for the last 3 months is 372,812 and the stock's 52-week low/high is $3.10500001/$11.9300003.

Kintara Therapeutics, Inc. (KTRA)

BioPharmCatalyst, Stocklight, NewsQuantified, FX Empire, AI Stock Finder, MarketWatch, Stockhouse, Nasdaq, Fintel, docoh, Seeking Alpha, EOD Data, Invest Chronicle, Barchart, Finviz, last10k, TradingView, GuruFocus, Dividend.com, Investing.com, Market Screener, Stockopedia, News Daemon, Morningstar, PR Newswire, YCharts, Dividend Investor, Wallet Investor, and Market Chameleon reported earlier on Kintara Therapeutics, Inc. (KTRA), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Kintara Therapeutics, Inc.’s commitment is to the development of novel cancer therapies for patients with unmet medical needs. The Company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with decreased risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. The Company previously went by the name DelMar Pharmaceuticals, Inc. It changed its name to Kintara Therapeutics, Inc. in August of this year. Established in 2009, Kintara Therapeutics is based in San Diego, California and lists on the NasdaqGS.

Additionally, the Company is advancing its proprietary late stage photodynamic therapy (PDT) platform. This platform holds promise as a localized cutaneous or visceral tumor treatment and also in other potential indications.

VAL-083 is a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action, which has demonstrated clinical activity against a range of cancers, including central nervous system (CNS), ovarian, and other solid tumors in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara Therapeutics’ internal research programs and these prior NCI-sponsored clinical studies, the Company is presently conducting clinical trials to support the development and commercialization of VAL-083 in GBM (glioblastoma multiforme).

REM-001 therapy has been previously studied in four Phase 2/3 clinical trials in patients with CMBC, who had before received chemotherapy and/or failed radiation therapy. With clinical efficacy to date of 80 percent complete responses of cutaneous metastatic breast cancer (CMBC) evaluable lesions and with an existing strong safety database of roughly 1,100 patients across numerous indications, the Company is advancing the REM-001 CMBC program to late stage pivotal testing.

At the beginning of September, Kintara Therapeutics announced the private placement of Series C Convertible Preferred Stock to accredited investors. Including the earlier announced closings, the Company received aggregate gross proceeds of about $25 million before deducting placement agent fees and other offering expenses payable by Kintara.

The capital raised from existing and new investors is expected to facilitate Kintara Therapeutics’ strategic initiative to become a recognized leader in developing therapies for rare and difficult to treat oncology indications. Its intention is to use the net proceeds from the offering mainly to fund the earlier announced registration study for VAL-083 in newly-diagnosed and recurrent GBM and the 15-patient REM-001 confirmatory lead-in study designed to seamlessly transition into a Phase 3 pivotal study for CMBC and also for working capital.

Kintara Therapeutics, Inc. (KTRA), closed Wednesday's trading session at $1.60, off by 5.8824%, on 431,676 volume with 1,218 trades. The average volume for the last 3 months is 658,931 and the stock's 52-week low/high is $0.379999995/$1.95000004.

Lightbridge Corporation (LTBR)

Stocktwits, OTC Markets, Stock News Now, Zacks, MacroTrends, Street Insider, last10k, Market Screener, Barchart, Investing.com, Newsheater, Nasdaq, Proactive Investors, ChartMill, Investcom.com, TradingView, PR Newswire, YCharts, InvestorsHub, EarningsCast, Morningstar, Stockaholics, Simply Wall St, Finviz, Seeking Alpha, Stockhouse, Street Insider, and GlobeNewswire reported beforehand on Lightbridge Corporation (LTBR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Lightbridge Corporation is an advanced nuclear fuel technology company. It is developing Lightbridge Fuel™. This is a proprietary next-generation nuclear fuel technology for current and future reactors, which substantially enhances the economics, safety, and proliferation resistance of nuclear power. Four large electric utilities that produce about half of America’s nuclear power advise Lightbridge on fuel development and deployment.

The Company formerly went by the name Thorium Power, Ltd. It changed its name to Lightbridge Corporation in September of 2009. Lightbridge is based in Reston, Virginia and lists on the NasdaqCM.

Lightbridge invented, patented, and has independently validated its technology, with objectives of preventing climate change and enhancing national security. The Company has assembled a world-class development team. Lightbridge plans to operate under a licensing and royalty model, and based on the increased power generated by Lightbridge-designed fuel, expects to offer high ROI (Return on Investment) for operators of existing and new reactors.

Lightbridge Fuel™ operates approximately 1000 °C cooler than standard fuel. The Company’s chief focus is on new metallic fuel rods, which it believes are significantly more economical and safer than traditional fuel. Using Lightbridge Fuel™ results in a lower reactor operating temperature. Furthermore, Lightbridge believes it adds incremental electricity at a lower cost than any other means of producing baseload electric power.

Concerning Fabrication, Lightbridge Fuel™ has three components that are metallurgically bonded during the fabrication process. This bonding improves fuel rod integrity, thermal conductivity, and eliminates a source of fission product release in the event of a bonded barrier breach. As a result, this reduces potential radiation exposure for plant workers. Lightbridge’s fuel boosts power output and extends the length of the fuel cycle.

Last month, Lightbridge announced that it received a Notification of Patent Grant from the Korean Intellectual Property Office for a divisional patent application relating to a co-extrusion method of manufacturing Lightbridge four-lobe helically twisted metallic fuel rods, based on the Company’s 2011 Patent Cooperation Treaty (PCT) patent application. Over the past year, Lightbridge has secured patents in Eurasia, Australia, Japan, South Korea, Canada, as well as the European Union (EU).

Mr. Seth Grae, President & Chief Executive Officer of Lightbridge, said, “Our latest patent award from the Korean Intellectual Property Office for a method to manufacture our Lightbridge Fuel™ rods further enhances our growing intellectual property portfolio. There are currently 24 reactors in South Korea that provide one-third of the county’s electricity, making this an attractive potential market for our fuel.”

Lightbridge Corporation (LTBR), closed Wednesday's trading session at $3.80, up 3.5422%, on 31,095 volume with 259 trades. The average volume for the last 3 months is 62,910 and the stock's 52-week low/high is $1.71000003/$9.60000038.

ReShape Lifesciences, Inc. (RSLS)

Morningstar, Street Insider, Netcials, AI Stock Finder, SmarterAnalyst, 4-Traders, Stockopedia, Accesswire, InvestorsHub, ETF.com, PR Newswire, GuruFocus, Market Screener, Nasdaq, Wallet Investor, TradingView, Stockwatch, Insider Financial, TMXmoney, Seeking Alpha, Investing.com, YCharts, Simply Wall St, and Barchart reported previously on ReShape Lifesciences, Inc. (RSLS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

ReShape Lifesciences, Inc. is a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases. Its present portfolio includes the LAP-BAND® Adjustable Gastric Banding System and the ReShape Vest™, an investigational device, to help treat more patients with obesity. The Company formerly went by the name EnteroMedics, Inc. It changed its corporate name to ReShape Lifesciences, Inc. in October of 2017. Founded in 2002, the Company is based in San Clemente, California. ReShape Lifesciences lists on the OTC Markets Group’s OTCQB.

The design of the Food and Drug Administration (FDA)-approved LAP-BAND® Adjustable Gastric Banding System is to provide minimally invasive long-term treatment of severe obesity. It is an alternative to more invasive surgical stapling procedures, including the gastric bypass or sleeve gastrectomy. The LAP-BAND® procedure helps to lessen the amount of food consumed at one time. The design of LAP-BAND® is to help one lose excess weight at a gradual and healthy pace. The LAP-BAND® can be adjusted to meet one’s personal needs and weight loss goals.

The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device. It wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. The intention of the ReShape Vest™ System is to enable fast weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

The Company’s ReShapeCare™ Virtual health coaching program is a virtual tele-health weight management program. It supports lifestyle changes for all weight-loss patients, to help them keep the weight off over time.

Last week, ReShape Lifesciences announced preclinical research demonstrating its investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) proprietary device for the treatment of type 2 diabetes mellitus (T2DM) was well-tolerated and met the study endpoints. The study was conducted as a part of the National Institutes of Health (NIH) Small Business Innovation Research Phase I grant that was earlier awarded August 1, 2019.

Mr. Bart Bandy, President & Chief Executive Officer of ReShape Lifesciences, said, “Our exploration of neuromodulation for diabetes aligns with the ReShape Lifesciences™ corporate strategy to build our portfolio and pipeline with technologies and services that improve the treatment of obesity and metabolic diseases. Based on these positive outcomes, the preclinical study represents a successful completion of the NIH Phase I grant and we look forward to advancing this unique diabetes focused innovation."

ReShape Lifesciences, Inc. (RSLS), closed Wednesday's trading session at $3.75, up 15.3846%, on 1,613 volume with 10 trades. The average volume for the last 3 months is 1,632 and the stock's 52-week low/high is $1.13999998/$14.25.

H/Cell Energy Corporation (HCCC)

Financial Buzz, All Penny Stocks, OTC Markets, Street Insider, Uptick Newswire, YCharts, Fairly Valued, MarketBeat, 4-Traders, Stockwatch, Stockopedia, Dividend Investor, Market Wire News, Market Screener, Simply Wall St, EIN Presswire, Stockhouse, last10k, Wallet Investor, Morningstar, and Equities reported previously on H/Cell Energy Corporation (HCCC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

H/Cell Energy Corporation designs and implements clean energy solutions featuring hydrogen and fuel cell technology. It is an integrator that concentrates on the design and implementation of clean energy solutions. This includes solar, battery, fuel cell, and hydrogen generation systems. By way of its subsidiaries, the Company also provides environmental systems and security systems integration. OTCQB-listed, H/Cell Energy is headquartered in Dallas, Texas.

The Company serves the residential, commercial, and government sectors. It has developed and implemented a hydrogen energy system used to completely power a residence or commercial property with clean energy. This is so it can run independent of the utility grid and also provide energy to the utility grid for monetary credits. The inventive system uses renewable energy as its source for hydrogen production.

The design of the HC-1 system is to provide clean energy for a better environment. The system eliminates the electric bill and dependence on fossil fuels. Additionally, it allows one to benefit with tax and energy credits while helping make the environment safe for future generations.

The HC-1 system is totally scalable. Upon installation, the HC-1 system operates as a self-sustaining energy system providing electricity and/or hydrogen fuel for transportation.

The design of each HC-1 system is to accommodate the electrical loads for an end user. The system can be configured to meet any kilowatt hour (kWh) demands. The installation includes solar panels, a hydrogen generator, a fuel cell, and a tank, which would be located exterior to the property with the battery system located interior to the property.

Recently, H/Cell Energy announced financial results for its Q1 ended March 31, 2020. For the three months ended March 31, 2020, the Company generated Revenue of $1,667,947 and a Net Loss of $261,761, which includes $68,701 of non-cash charges that do not affect the cash flow performance or working capital of H/Cell Energy. This amounts to a $(0.04) per share loss. Comparatively, for Q1 ended March 31, 2019, the Company generated Revenue of $1,704,273 and a Net Loss of $143,638 which included $111,153 of non-cash charges. This amounted to a $(0.02) per share loss.

H/Cell Energy Corporation (HCCC), closed Wednesday's trading session at $0.20, up 63.9344%, on 16,574 volume with 4 trades. The average volume for the last 3 months is 3,235 and the stock's 52-week low/high is $0.109999999/$0.844799995.

Meso Numismatics, Inc. (MSSV)

RedChip, OTC Dynamics, TeleTrader, Last10k, TipRanks, Street Insider, Nasdaq, Simply Wall St, Investing.com, Financial Buzz, Dividend Investor, Otc.watch, InvestorsHub, MarketWatch, Stockwatch, Investors Hangout, GlobeNewswire, New Media Wire, Stockhouse, Wallet Investor, and TradingView reported earlier on Meso Numismatics, Inc. (MSSV), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Meso Numismatics, Inc. is a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean. It has become the primary hub for rare, exquisite, and valuable inventory from the Meso Region and worldwide. The Company was previously known as Pure Hospitality Solutions, Inc. It changed its name to Meso Numismatics, Inc. as a result of its merger with Meso Numismatics, Corp. in September of 2018. Meso Numismatics has its head office in Boca Raton, Florida.

Meso Numismatics is the only Company in the Central American-Caribbean region that is an on-the-ground registered dealer with the Numismatic Guaranty Company (NGC) and the Paper Money Guaranty (PMG). The Company has a selection of rare inventory, and also has a specialized App for banknote recognition, available on Google Play and the Apple App Store. Meso continues to partner with some of the largest auction houses internationally for the sale of the Company’s rarer inventory.

Meso Numismatics was established in September 2016 by a group of devoted coin collectors and currency seekers from the Mesoamerica area - from Mexico to Panama. The Company specializes in this area of the region. Moreover, Meso also has inventory and clients from all over the world. Numismatics is the study or collection of currency. This includes coins, tokens, paper money, as well as related objects.

In September, Meso Numismatics announced that it has preliminarily completed the due diligence phase of the Green Pay acquisition and is now set to proceed with an audit of Green Pay to be performed by the Company’s independent registered accounting firm. According to Management, Meso’s counsel will soon begin preparing the definitive purchase agreement for the Green Pay acquisition.

Afterward, the expectation is that Meso Numismatics will issue shares of its Preferred Stock as an initial payment for the acquisition. Following that, its U.S. independent registered accounting firm will start to audit Green Pay’s financials, preparing them to be included in Meso’s SEC filings at some later date.

At present, Green Pay hosts 110 independent stores located around Central America; processes around $2.5M in monthly transactions among all of its users; and executes roughly 500,000 transactions per month. Green Pay also has approximately 400,000 monthly active users; and has about 650,000 registered credit cards representing multiple payment institutions around Central America.

Meso Numismatics, Inc. (MSSV), closed Wednesday's trading session at $0.014, up 37.2549%, on 63,643 volume with 6 trades. The average volume for the last 3 months is 39,893 and the stock's 52-week low/high is $0.007199999/$0.089900001.

Whiting USA Trust II (WHZT)

Zacks, Street Insider, All Stocks Today, Wallstreet Online, Stockhouse, Global Banking and Finance, Simply Wall St, Marketbeat, MarketWatch, Barchart, and Dividend Investor reported previously on Whiting USA Trust II (WHZT), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Whiting USA Trust II holds a term net profits interest in the oil and gas producing properties located in the Permian Basin, Rocky Mountains, Gulf Coast, and Mid-Continent regions. Whiting USA Trust II is a subsidiary of Whiting Petroleum Corporation. The Company lists on the OTC Markets. Established in 2011, Whiting USA Trust II has its corporate office in Houston, Texas.

As of December 31, 2018, the Company’s oil and gas properties included interests in roughly 367.8 net producing oil and natural gas wells. These are situated in 46 predominately mature fields with established production profiles in 10 States.

Recently, Whiting USA Trust II announced that the Trust would make a distribution to unitholders in the second quarter of 2019. This relates to net profits generated during the first quarterly payment period of 2019. Unitholders of record on May 20, 2019 received a distribution of $0.140750 per unit that was payable on or before May 30, 2019.

The Trust’s net profits interest (NPI), the only asset of the Trust other than cash reserves held for future Trust expenses, represents the right to receive 90 percent of the net proceeds from Whiting Petroleum Corporation’s interests in certain existing oil and natural gas properties located mainly in the aforementioned Rocky Mountains, Permian Basin, Gulf Coast and Mid-Continent regions of the U.S.

As of March 31, 2019, on a cumulative accrual basis, 9.24 MMBOE (87 percent) of the Trust’s total 10.61 MMBOE have been produced and sold or divested. Based on the Trust’s reserve report for the underlying properties as of December 31, 2018, the projection is that the Trust’s 10.61 MMBOE will be produced prior to December 31, 2021, shortly after which the Trust would terminate. The 2018 year-end reserve report reflects expected annualized production decline rates of roughly 11.1 percent for oil and 23 percent for gas between 2019 and 2021.

The Company’s parent, Whiting Petroleum Corporation, is an independent oil and gas company. It develops, produces, acquires and explores for crude oil, natural gas and natural gas liquids mainly in the Rocky Mountains region of the U.S. The Company’s largest projects are in the Bakken and Three Forks plays in North Dakota and Montana and the Niobrara play in northeast Colorado.

Whiting USA Trust II (WHZT), closed Wednesday's trading session at $0.099, up 41.0256%, on 26,886 volume with 13 trades. The average volume for the last 3 months is 46,318 and the stock's 52-week low/high is $0.039999999/$1.00.

Rainforest Resources, Inc. (RRIF)

High Rising Stocks, OTC Markets, Stockhouse, InvestorsHub, 4-Traders, TradingView, Simply Wall St, Wallet Investor, Barchart, MarketWatch, YCharts, Penny Stock Hub, Wallmine, Stockopedia, Stockflare, Investing News Alerts, and Wall Street Pennies reported earlier on Rainforest Resources, Inc. (RRIF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Rainforest Resources, Inc.’s mission is to protect the ecosystems of the rainforest to reduce the impact of global warming. Rainforest Resources operates in the forestry sector. As part of its dedication to prevent global warming, the Company is making the best of efforts to preserve the rainforest, the initial phase being the “Huamboya Forest” Morona Santiago – Ecuador. At Huamboya, millenary trees and endemic species of the Amazon, terrestrial, aquatic, as well as aerial are found. Rainforest Resources has its U.S. office in Anna Maria, Florida.

The Company, in its dedication to ease global warming, commits all its efforts and economic support for the conservation of the humid forest. Furthermore, it produces carbon credit certificates and develops and exports natural spring water.

Rainforest Resources’ positions are in tropical rain forests, land for reforestation, and above all clean air. The Company’s vision is to sustain forestry and to live in harmony with forestry in itself.

Rainforest Resources is interested in conserving the Huamboya ecosystem. Huamboya presents a Humid Tropical Megathermal climate. The forest is covered by native forest without human intervention.

The Huamboya forest has about 586 endemic plant species of which 45 percent are orchids. The forest has a rich diversity of animal life. This includes 343 species of birds, 100 species of mammals, and more than 500 species of vertebrates.

Recently, Rainforest Resources announced, by way of its subsidiary Rain Forest Enterprises SA, that it purchased from Latitude Aerospace Solutions (LAS) a state of the art Drone model VTOL. When fitted with remote sensors, the Drone can detect the effect of greenhouse gases in a given area and provide data on CO2 and Oxygen levels. This is important information used in the computation for the issuance of Verified Emission Reductions (VERs)/Certified Emission Reductions (CERs).

The initial use of the Drone will be in the evaluation of Rainforest Resources’ rain forest properties in Ecuador to produce Verified Carbon Credit Certificates. Subsequently, it is the Company’s intention to provide the Drone services to other entities involved in the ecological preservation of the rainforests in Ecuador on a cost-plus basis. This will provide additional income to Rainforest Resources.

Rainforest Resources, Inc. (RRIF), closed Wednesday's trading session at $1.87, up 33.5714%, on 10,211 volume with 49 trades. The average volume for the last 3 months is 6,532 and the stock's 52-week low/high is $0.215100005/$7.5999999.

Black Cactus Global, Inc. (BLGI)

StreetInsider, Insider Financial, The Street, 4-Traders, Morningstar, Stockopedia, Dividend Investor, PennyStockHub, Stockhouse, Simply Wall St, MarketNewsUpdates, Tip Ranks, Stockwolf, Barchart, InvestingNewsAlerts, Stock Press Daily, InvestorsHub, OTC Markets, and InvestorsHangout reported previously on Black Cactus Global, Inc. (BLGI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Black Cactus Global, Inc. is a technology development business focusing on Blockchain, machine learning, cryptocurrency, and the Internet of Things (IoT). Its corporate mission is to pioneer the application of Blockchain and overlapping technologies to protect IP (Intellectual Property) and the security of data and financial transactions. The Company is developing Blockchain applications for FinTech, Healthcare, Media and Supply Chain employing smart contracts and machine learning. Black Cactus Global is based in Las Vegas, Nevada.

The Company’s strategic plan is to become the first totally integrated digital financial institution with Blockchain technology as its operating foundation. Black Cactus Global’s services include Blockchain Applications, Trading Exchange, KYC/AML Biometrics, Music Exchange, and Card Programs and Payment Systems.

In addition, its services include Crypto Currencies, Internet of Things (IoT), Smart Contracts, as well as FinTech & MedTech. Black Cactus Global specializes in worldwide development and consulting projects in its key development areas of FinTech, digital media, financial services, KYC, AML, cyber security, and healthcare.

Black Cactus Global announced in January of this year that it entered into an MOU (Memorandum of Understanding) with the majority shareholders in an Indian Technology firm to establish a subsidiary of the Company. With the MOU, Black Cactus Global will become the largest stakeholder of a global Technology company with offices in the ‘FinTech Valley’ Vizag Software Technology Park in Visakhapatnam, India, through which it will center on and advance the use of its innovative Blockchain based IP.

In May 2018, Black Cactus Global announced that it completed a share exchange agreement with the Blockchain development subsidiary, Black Cactus Global Technologies Pvt. Limited (BCG-TPL). The agreement calls for Black Cactus Global to own an initial 29 percent interest in BCG-TPL, which has already attained major milestones that will enable Black Cactus to scale-up development activities.

Regarding Healthcare, Black Cactus Global concentrates on creating opportunities for digital health economies via Blockchain with AI, IoT, and Machine Learning. Pertaining to Energy, the Company offers privatized network grid provision to isolate green energy from traditional energy sources and a chain code logic to manage energy distribution and estimation.

Black Cactus Global, Inc. (BLGI), closed Wednesday's trading session at $0.0194, up 85.3798%, on 744,320 volume with 45 trades. The average volume for the last 3 months is 489,507 and the stock's 52-week low/high is $0.001/$0.049499999.

Nickel Creek Platinum Corp. (NCPCF)

InvestorsHub, InvestorX, The Frugal Forager, Northern Miner, Stockhouse, Metals News, Business Insider, OTC Markets, Investors Hangout, Wallmine, and Portfolio Sharing reported earlier on Nickel Creek Platinum Corp. (NCPCF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Nickel Creek Platinum Corp. is a mining exploration and development company headquartered in Toronto, Ontario. Its focus is on advancing its 100 percent-owned Nickel Shäw Project with the aim of creating Canada's next world-class nickel sulphide mine. The Company previously went by the name Wellgreen Platinum Ltd. It changed its corporate name to Nickel Creek Platinum Corp. in January of this year. Nickel Creek Platinum lists on the OTC Markets Group’s OTCQX.

The 100 percent-owned Nickel Shäw project is positioned in the southwest of Canada’s Yukon Territory, around 317 km northwest of the capital, Whitehorse. The Project has excellent access to infrastructure, located three hours west of Whitehorse via the paved Alaska Highway, which further provides year-round access to deep-sea shipping ports in southern Alaska.

Nickel Shäw is host to more than 2 billion pounds of nickel, 1 billion pounds of copper, 6 million ounces of platinum group metals (PGM's) and 120 million pounds of cobalt in the Measured and Indicated categories. The Nickel Shäw Property lies within the Kluane First Nation core area as defined by their treaty with Canada and the Yukon Government.

Nickel Creek Platinum reported this past July the final results of its Phase II Metallurgical Program on the Nickel Shäw Project. The Phase II Metallurgical Program succeeded in its primary objective of separating bulk CuNi concentrate into separate saleable nickel and copper concentrates. This represents the most in-depth and comprehensive metallurgical undertaking completed so far at the Project.

Recently, Nickel Creek Platinum announced an update on the status of its Nickel Shäw Project. Following the conclusion of the Company’s Phase II Metallurgical Program, it embarked on more work toward completing a Preliminary Economic Assessment (PEA). During the course of the Phase II Metallurgical Program, it reported that it identified a strong correlation between nickel recovery and total sulphide content.

Particularly, it was determined that the presence of sulphides (sulphur in pyrrhotite) was an important marker of nickel recovery. This means that the areas of higher sulphur yielded higher recoveries, and areas of lower sulphur yielded lower recoveries, irrespective of nickel head grade, which remains relatively consistent throughout the deposit.

Nickel Creek Platinum Corp. (NCPCF), closed Wednesday's trading session at $0.12, up 30.8615%, on 1,328,235 volume with 148 trades. The average volume for the last 3 months is 170,528 and the stock's 52-week low/high is $0.0171/$0.125200003.

NowNews Digital Media Technology Co. Ltd. (NDMT)

CapitalCube and OTC Markets reported on NowNews Digital Media Technology Co. Ltd. (NDMT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

NowNews Digital Media Technology Co. Ltd. (NowNews) is a media enterprise. The OTCQB-listed Company provides news and multimedia platform services. In essence, NowNews is a media holding company concentrating on the worldwide Chinese market. The Company’s holdings in the media space include digital media, movie production and distribution, and music copyright. NowNews is headquartered in Taipei City, Taiwan.

The Company’s digital media business engages in creating, collecting, and distributing news and information through its website and applications on mobile phones or tablets. Its subsidiary is NOWnews Network Co. Ltd. (NOWnews). This is the largest online self-produced news content provider of Taiwan. Furthermore, it is the only Taiwanese online news website fully accessible in Mainland China.

NowNews’ movie production and distribution business engages in Internet movie, Internet drama, and Internet show production. It also engages in foreign movie import and production, movie marketing and advertising, and the Internet personality business.

NowNews’ music copyright business owns copyrights to over 3,000 hit pop songs. This business provides a complete range of Karaoke products. Additionally, NowNews has investments in the banking industry in Southeast Asia.

Recently, NowNews Digital Media announced that its majority-owned subsidiary, NOWnews Network Co. Ltd. (NOWnews), agreed to cooperate with Grace Intelligent Blockchain Technology Co. Ltd. to build a blockchain based media platform. NOWnews will build a new decentralized blockchain based media platform.

On the platform, the online network users will be divided into four roles. These are author, reviewer, reader, and storage provider. On this decentralized platform, people worldwide can become authors and publish local news.

China Information Technology, Inc. (CNIT) announced recently that it entered into an exclusive distribution agreement with NowNews Digital Media Technology. CNIT is a foremost provider of internet-based ad distribution and ad display terminal sharing systems in China. With this agreement, NowNews will act as the exclusive partner of CNIT in Taiwan to promote CNIT’s new-media sharing business.

NowNews Digital Media Technology Co. Ltd. (NDMT), closed Wednesday's trading session at $0.85, up 61.9048%, on 200 volume with 1 trade. The average volume for the last 3 months is 17 and the stock's 52-week low/high is $0.010999999/$1.00.

The QualityStocks Company Corner

DarioHealth Corp. (NASDAQ: DRIO)

The QualityStocks Daily Newsletter would like to spotlight DarioHealth Corp. (DRIO).

DarioHealth Corp. (NASDAQ: DRIO) was featured today in a publication from BioMedWire, examining how genetic testing and counseling services may help in determining if a person has the BRCA1 and BRCA2 gene mutations. Some people may have an inherited mutation in either one or both of these genes that increases their risk of breast cancer. These mutations can be passed to an individual from either of their parents and can affect both men and women. Also today, the company was featured in a publication from BioMedNewsBreaks, examining how today announced that Eric Milledge has joined DarioHealth as chairman of the company's newly-established Scientific Advisory Board (“SAB”). Milledge has dedicated his entire career to the field of health care, with a focus on pharmaceuticals and medical devices, and spent 34 years at Johnson & Johnson, building a vast network of relationships across the health-care landscape.

New York and Israel-based DarioHealth Corp. (NASDAQ: DRIO) leads global digital therapeutics (DTx) with its popular, smartphone-centered personalized chronic illness management software-as-a-service (SaaS). The company’s strategic advantages include:

  • AI-powered digital solutions that drive durable behavior change in chronic disease patients, and
  • Personalized user experience at scale to make behavior change the path of least resistance.

Approximately $3 trillion in annual U.S. costs associated with chronic illnesses like diabetes, hypertension and obesity are largely preventable with behavioral therapies. Formerly limited to periodic office visits, these therapies can now scale to millions with tech-enabled, continual and remote health monitoring, as well as AI-driven digital and live coaching. This is all possible while still maintaining the personalization required for success in reducing illness and its related effects and costs.

Roughly 51,000 active, paying users manage their health with Dario’s platform that combines smartphone-connected vitals measurement, remote patient monitoring (RPM), lifestyle management tools, and AI-driven and human coaching to deliver improved clinical outcomes.

Among the most downloaded medical apps, the Dario platform is rated at 4.9 stars on the Apple App Store and features 11,000 reviews, along with a Net Promoter Score (a measurement of consumers’ willingness to recommend the product to others) that’s the highest in its field.

Company Strategy

Clinical studies demonstrate Dario’s direct improvement on users’ health measures like H1AC scores (diabetes) and blood pressure (hypertension).

Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.

Proprietary data analysis provides valuable insights that not only improve health care providers’ medical capabilities but, through artificial intelligence, encourage patients to take evidence-based and highly personalized preventative measures that reduce risk, emergency room visits and preventable hospitalization.

Dario is now deploying its successful B2C platform in B2B2C, targeting employers and health plans with competitive advantages in cost, software and hardware.

The company estimates an annual addressable U.S. market of $72 billion, only 1% of which has been penetrated with digital therapeutics.

The strategic transition to B2B2C (from exclusively B2B) is intended to accelerate revenue growth by reducing Dario’s cost per acquisition per user and expanding margins.

Dario’s commitment to aggressive growth is also shown by its appointment of a new president, chief medical officer and head of sales for North America, all from a highflyer behavioral health company.

Key growth drivers planned include expansion of the company’s paying B2C subscriber base; lateral expansion into other chronic conditions that overlap with its core diabetes populations, such as hypertension, obesity and depression; and increased B2B2C penetration.

Financial Highlights

The company plans to leverage a massive opportunity for growth, with a global addressable market for digital therapeutics of roughly $108 billion. In the U.S. alone, that number is estimated at $72 billion, and only about 1% of that market has been penetrated.

Dario’s strategic transition to an SaaS membership business model increased gross profit by 87% in Q1 2020, as compared to the prior year. Membership revenue increased from 27.1% to 46.7% in the same period. The company is seeing improved operating efficiencies as it shifts focus to the B2B2C business model, and it expects average revenue per user per month (ARPU), which was $6 and $25 in 2019 and 2020, respectively, to reach $70.

Value to Consumers and Businesses

Dario continually evaluates and optimizes the value and return its platform delivers to consumers and businesses.

Consumers seeking to understand how their everyday behavior impacts their personal health and chronic conditions benefit from actionable feedback on how to improve health and better collaborate with health care providers.

Businesses looking to increase employee satisfaction, loyalty and productivity with fewer health-related absences take advantage of Dario’s services for employers.

Health care providers improve patient compliance using the platform’s interactive services that allow for greater monitoring, which improve engagement with patients at the right times and with the right treatments.

Health plans can leverage DarioHealth’s solutions to improve patient outcomes and lower costs.

Recent Studies

The company recently presented the results of two new studies at the American Diabetes Association’s 80th Scientific Sessions, which showed sustained improvements in blood glucose levels and blood pressure among users of its digital therapeutic platform for chronic diseases. The results of these two studies demonstrate that the use of Dario’s therapeutic platform promotes behavioral modification, enhanced individual engagement and improved clinical outcomes.

Remote Patient Monitoring (RPM) Agreements

The Centers for Medicare & Medicaid Services recently approved RPM codes for Medicare patients, which enables physicians to bill for between-visit patient care.

This simplifies implementation of the company’s open and scalable AI-driven platform and further supports transition to the company’s high-margin, recurring SaaS model targeting B2B2C revenue channels.

Emergency COVID-19 FDA Guidelines Allow Self-Test Blood Glucose Meters

In an effort to preserve personal protective equipment (PPE) and reduce contact between health care providers and patients in hospital settings due to COVID-19, the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters, including Dario’s smartphone-connected metering device, may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.

As a result, hospitals can now allow patients to self-test using their Dario blood glucose testing strips and smartphone-connected devices, or hospitals can issue patients Dario devices upon admission for COVID-19-related conditions.

Irregularities in blood glucose levels are suspected as a factor in the increased severity of potentially deadly COVID-19 complications. As such, a high priority is being placed on stabilization of patients’ blood glucose levels.

Awards and Recognition

DarioHealth’s Blood Glucose Monitoring System was voted as the ‘Best Glucometer for Data Management’ by Top Ten Reviews. Jeph Preece, senior editor at Top Ten Reviews, said, “The Dario app is the best data management system that I’ve seen. Compared to apps by popular brands, Dario’s system looks and feels like it’s years ahead of the curve.”

‘The Global Digital Health 100’, an annual award sponsored by the reputable Journal of Health, recognized DarioHealth as a leader among health technology companies demonstrating the greatest potential to change the way that health care is delivered.

DarioHealth Corp. (DRIO), closed Wednesday's trading session at $18.40, up 3.1969%, on 63,876 volume with 687 trades. The average volume for the last 3 months is 251,429 and the stock's 52-week low/high is $3.01999998/$22.4899005.

Recent News

Creatd Inc. (NASDAQ: CRTD)

The QualityStocks Daily Newsletter would like to spotlight Creatd Inc. (NASDAQ: CRTD).

Creatd (NASDAQ: CRTD, CRTDW) (Formerly Jerrick Media Holdings Inc.), the parent company and creator of the Vocal platform, Tuesday announced the closing of its public offering of 1,725,000 units of securities at $4.50 per unit, for total proceeds of $7,762,500. According to the update, each unit consisted of one share of the company's common stock and one warrant to purchase one share of common stock, the warrant immediately exercisable at a price of $4.50 per share and expiring five years from the date of issuance. The company's common stock and warrants began trading on the Nasdaq Capital Market on September 11, 2020, under the symbols "CRTD" and "CRTDW," respectively. The company has granted underwriters a 45-day option to purchase 258,750 additional shares of common stock and/or 258,750 additional warrants to cover over-allotments, if any. To view the full press release, visit http://nnw.fm/9GRIV

Creatd Inc. (NASDAQ: CRTD) develops technology-based solutions to solve digital problems. Through the combination of design, thought and data analysis, the company builds products that influence a worldwide audience.

Creatd’s flagship product is Vocal, a proprietary long-form digital publishing platform that provides storytelling tools and engaged communities for creators to get discovered and fund their creativity.

Vocal

Designed to develop and cost-effectively engage content creators, the Vocal platform enables its over 500,000 registered content creators to reach an engaged audience and monetize their content. In addition to providing relevant content, Vocal’s technology is centered on efficiency and scalability through its niche digital communities, as well as output through its data-driven distribution strategy.

Vocal partners with content creators and brands that recognize difficulties inherent in the digital advertising space and that can benefit from branded content marketing opportunities available on publishing platforms like Vocal.

All content available on Vocal is created within the platform’s custom editor and published on one of Vocal’s embedded genre-specific communities, spanning topics that range from food to wellness, beauty, technology and more.

In May 2019, Creatd launched Vocal+, its premium subscription membership program. Vocal+ members pay a membership fee for premium value-added features, including receiving increased earnings for their content, reduced platform processing fees for tips received, a Vocal+ badge on their creator page, access to new features on the Vocal Platform, and other rewards. Creators can sign up for free or upgrade to Vocal+, available for purchase on either an annual or monthly subscription basis.

Vocal for Brands

Vocal for Brands is an in-house creative studio that generates actionable data from bespoke native advertising campaigns. Vocal for Brands partners with direct-to-consumer (DTC) to create beautiful, campaign-optimized stories on Vocal that build brand affinity, trust and drive results.

Additionally, Creatd provides a Managed Services offering to business-to-business (B2B) and business-to-consumer (B2C) product and service brands which encompasses a full range of digital marketing and e-commerce solutions. Managed Services includes the setup and ongoing maintenance of clients’ websites, Amazon and Shopify storefronts and listings, social media pages, search engine marketing, and other various tools and sales channels utilized by e-commerce sellers for sales and growth optimization. In addition to partnering with Managed Services clients, the company offers a range of la carte services.

Growth Strategy

On September 11, 2020, Creatd Inc. officially changed its name from Jerrick Media Holdings Inc. and uplisted its stock to the Nasdaq Capital Market. The company also announced the pricing of its underwritten public offering of 1,725,000 units of securities at an offering price of $4.50 per unit.

This rebranding initiated Creatd’s go-forward growth strategy and its plans to expand its offerings and provide technology products and resources for creators to help transform their ideas into reality. The strategic plan is designed to greatly increase Creatd’s potential market value via a plethora of new revenue streams.

Creatd focuses on a community of creators that includes more than 2.5 billion users, for which it will offer democratized, transparent platforms for distribution, sentiment, resources and monetization. The company’s agile development process will rely on a combination of bleeding-edge technology that eliminates barriers and creates efficiencies. Superior design thinking and data analysis will allow Creatd to expand its digital footprint to a global community.

Creatd intends to partner with a community of technology collaborators and sophisticated investors who collaborate to provide technology solutions for creators, brands and their respective audiences. The company’s solutions, business processes, technology platforms and design theories will lend themselves to application opportunities on a global scale.

History & Management

Creatd was founded in 2012. Initially a private media company providing online content through a portfolio of brands, Creatd’s needs quickly outpaced its initial technology and product offering. In 2015, Creatd partnered with Thinkmill, a premiere, Australia-based product design and development group to create a content management system (CMS) for its brands; that system evolved into the company’s flagship product, Vocal.

Today, Creatd’s management team is an impressive group of abstract thinkers united by their passion to solve problems. Leading the team are founder and CEO Jeremy Frommer, and Justin Maury, Creatd’s president and head of product.

Frommer’s career includes two decades in the financial technology industry, working as a hedge fund and portfolio manager, as well as on the sell-side of the financial industry. Frommer started NextGen Trading, a software development company building proprietary equity trading platforms. NextGen was acquired by Carlin Financial Group of which Frommer became CEO. RBC Capital Markets Corporation eventually bought Carlin. At RBC, Frommer was managing director, head of the Global Prime Services group and a member of the RBC Global Equities Operating Committee.

Maury joined Creatd in 2013, bringing with him 10 years of experience in the creative industry. Since partnering with Frommer to establish Creatd, Maury led the company’s product development for more than four years. His passion for the creative arts and technology ultimately yielded the vision for Vocal. During Creatd’s early formative years, Maury was a driving force in creating the vision, design and architecture for the Vocal platform and managing the oversight of technology development.

Creatd Inc. (NASDAQ: CRTD), closed Wednesday's trading session at $3.19, up 1.2698%, on 70,168 volume with 374 trades. The average volume for the last 3 months is 147,600 and the stock's 52-week low/high is $3.00/$3.77010011.

Recent News

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, has closed its previously announced agreement to acquire LD Micro, a leading data and event company serving the small and micro-cap space. Closing of the acquisition includes the issuing to LD Micro shareholders of 1.6 million shares of Class A common stock that are subject to lock-up for 36 months. In addition, SRAX will pay four $1 million quarterly installments; the first payment was made at closing. As a result, LD Micro will be a wholly owned subsidiary of SRAX. LD Micro founder and president Chris Lahiji will continue to serve in that capacity. In addition, Lahiji has been appointed to SRAX’s board of directors. To view the full press release, visit: http://nnw.fm/BUVrP

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Wednesday's trading session at $2.64, up 3.125%, on 95,956 volume with 390 trades. The average volume for the last 3 months is 139,679 and the stock's 52-week low/high is $1.04999995/$3.35739994.

Recent News

The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER)

The QualityStocks Daily Newsletter would like to spotlight The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER).

The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused drinking waters and CBD-infused products, today announced that its flagship brand, Alkaline88(R), is now available in over 200 new convenience store locations and across seven Core-Mark distribution centers. “We continue to make great strides toward our c-store strategy and see strong demand for our single-serve offerings,” said WTER president and CEO Ricky Wright in the press release. To view the full press release, visit: https://www.cnw.fm/Z0gRq. Also today, the company was featured in the 420 with CNW by CannabisNewsWire. Twitter has partnered up with the Substance Abuse and Mental Health Services Administration to advocate for substance misuse treatment. When a Twitter user searches for “marijuana” or any other substance-related keyword, health warnings will appear. However, it turns out this only applies to marijuana.

Founded in 2012, The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes, along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked label ‘Clean Beverage’. Quickly being recognized as a growing lifestyle brand, Alkaline88® launched A88 Infused™ in 2019 to meet consumer demand for flavor-infused products. A88 Infused™ flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched the A88CBD™ brand, featuring a broad line of topical and ingestible products. These products are made with lab-tested full and broad-spectrum hemp and include salves, balms, lotions, essential oils, bath-salts, CBD infused drinks, tinctures, capsules, gummies and powder packs.

Innovation and Expansion

Founded in 2012, The Alkaline Water Company began with a mission to create the best-tasting water in the world. At the time, there were two emerging trends in health-conscious consumers: a growing interest in the alkaline diet and perceived health benefits of pink Himalayan rock salt. By combining these two concepts in an alkaline water and trademarking the name Alkaline88, The Alkaline Water Company began offering what it calls the smoothest tasting Clean Beverage™ in the U.S. enhanced-water category.

Now a top bulk alkaline-water brand (the company reported record sales in March and April 2020, surpassing March and April 2019 numbers by 114% and 171%, respectively), The Alkaline Water Company is committed to growing its national footprint through innovation and expansion. That mindset was evident as the company introduced eco-friendly aluminum bottles and branched out into flavor-infused waters; the company currently offers six different flavors: peach/mango, lemon/lime, raspberry, watermelon, blood orange and lemon.

The company’s commitment to innovation may be most evident in its newest product line: A88CBD. This line of CBD-infused products includes tinctures, capsules, gummies, salves, balms, hand and foot lotions, essential oils, bath bombs and bath salts, as well as CBD-infused drinks, water and beverage shots. These quality, CBD-infused offerings are all made with lab-tested, full-spectrum hemp and are conveniently packaged and perfect for on-the-go or at home use.

In addition, The Alkaline Water Company has implemented an aggressive growth strategy, with numerous organic initiatives focused on national multichannel, mass-market expansion through a direct-to-warehouse model and co-packing facilities that are strategically located within 600 miles of 95% of the U.S. population. In addition to this strong brick-and-mortar approach, the company recently launched a B2C e-commerce platform (www.A88CBD.com) and aggressive digital-marketing campaigns.

Clear Advantages in a Growing Market

With consistent growth year over year, the company reported $32.2 million in revenue in fiscal 2019 and has emerged as a growth leader in the functional (value-added) waters space, which is the fastest-growing segment of the bottled water industry.

The Alkaline Water Company’s efforts are focused on its clear competitive advantages, including its strong marketing (the inclusion of alkaline in product names); existing grocery channels, which feature excellent relationships and a nationwide broker network; distinctive branding; proprietary technology, which produces great-tasting, high-quality water, infused drinks and other products; and price, with a broad range of products in all formats, from bulk bottles to single serve.

As the company focuses on strategic growth, it is eyeing the impressive potential of a market that is on a strong upswing. Annual bottled water sales have now surpassed soda consumption, with soda sales in the United States having declined by $1.2 billion over the past five years. Some research indicates that the global bottled water market will reach an estimated $280 billion this year, while the CBD market is forecast to top $20 billion by 2024.

With its products available in all major trade channels, including grocery stores, drug stores, c-stores and big-box retailers, The Alkaline Water Company is also looking to expand into new spaces, such as health and beauty, hospitality and specialty retailer locations.

Seasoned Management Team

The Alkaline Water Company is led by an experienced team focused on the company’s core strategy of building a national retail footprint and extending its lifestyle brands into other consumer packaged goods categories.

Richard A. Wright, President, CEO and Co-Founder of The Alkaline Water Company Inc., oversees all aspects of the business, successfully guiding the company through strategic opportunities and delivering greater than 50% growth since the company’s inception. A passionate and versatile leader with a strong track record of innovation, collaboration and achieving goal-driven results, Wright is a serial entrepreneur with more than 41 years of experience. Early in his career, he spent years at one of the ‘Big Four’ accounting firms, working his way up to Regional Director of Tax and Financial Planning. As a CPA, entrepreneur and former CFO, Wright brings extensive knowledge of finance, operations, sales and marketing to the team, and he has participated in hundreds of M&A transactions throughout his career.

David Guarino, CFO, Secretary, Treasurer and Director, earned a Bachelor of Science in accounting and a Master of Accountancy from the University of Denver. From 2008 to 2013, Guarino was President and a Director of Kahala Corp., a worldwide franchisor of multiple quick-service restaurant brands with locations in 49 states and more than 25 countries. From 2014 to 2015, Guarino was President of HTI International Holdings Inc., a technology company focused on forward osmosis water filtration technology.

Frank Chessman, National Sales Manager, is a graduate of the University of Southern California’s Marshall School of Business. He spent 25 years with Ralph’s Grocery, Kroger’s largest division, working at many levels before ultimately becoming Vice President of Advertising & Marketing. He then served 14 years as Executive Vice President at Simon Marketing. Chessman has more than a decade of experience in the beverage manufacturing industry.

Brian Sudano, Director, is managing partner of Beverage Marketing Corporation and BMC Strategic Associates. Sudano’s experience covers nearly the entire beverage industry, from energy drinks to wine, with special expertise in beverage alcohol by virtue of varied industry experience across a broad range of projects. Sudano manages several major clients, providing ongoing strategic and market advice and leading projects in strategic planning, market entry analysis and planning, sales/distribution, business modeling, brand repositioning and international opportunity assessment. He has spoken at many beverage industry events and is a contributing editor at Beverage World magazine.

Aaron Keay, Chairman, has been a successful investor, entrepreneur and financier to multiple small cap and startup companies over the last decade. During his time with these companies, he served in advisor, board-member and senior-management roles. His experience ranges across multiple sectors in mining, biotech, health and wellness, tech and cannabis, where he has invested and raised more than $500 million.

The Alkaline Water Company Inc. (NASDAQ: WTER), closed Wednesday's trading session at $1.36, up 2.2556%, on 1,009,699 volume with 3,178 trades. The average volume for the last 3 months is 000,000 and the stock's 52-week low/high is $0.400000005/$2.5999999.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has announced that it will be presenting at the upcoming LD 500, an investor conference set to take place in an entirely virtual setting Sept. 1-4, 2020 (http://ibn.fm/42UBB). With 500 handpicked companies in attendance, this year’s conference is set to be among the largest micro-cap focused events globally with thousands of investors expected to attend.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Wednesday's trading session at $0.895, up 4.0698%, on 611,437 volume with 996 trades. The average volume for the last 3 months is 902,498 and the stock's 52-week low/high is $0.810000002/$6.25.

Recent News

Cybin Corp.

The QualityStocks Daily Newsletter would like to spotlight Cybin Corp..

Cybin Corp., a Canadian early-stage life sciences company appears ideally positioned in two promising markets: nutraceuticals and psychedelic drugs. Both sectors are projected to see impressive growth in the coming years. Cybin looks to benefit from its growing footprint in both spaces. In 2019, the global nutraceutical market was valued at $382.51 billion. The market is also expected to grow at a compound annual growth rate (“CAGR”) of 8.3% over the next seven years. Consumers continue to embrace functional foods, or foods that offer benefits beyond basic nutrition, for their wellness benefits (http://ibn.fm/1UQMB).

Cybin Corp. is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.


Recent News

chart

180 Life Sciences Corp.

The QualityStocks Daily Newsletter would like to spotlight 180 Life Sciences Corp..

The sudden and surprise impact of the COVID-19 pandemic this year has drawn new attention to the bioreactive intricacies of the inflammatory process (http://ibn.fm/tWUgV) as medical scientists work feverishly to develop a clear response to the crisis that has killed some 900,000 people worldwide (as of September 2020) with millions more seriously affected (http://ibn.fm/U1hfy). Even before the virus began its sweep, inflammation was receiving critical attention from rheumatologists because of its significance to a wide array of diseases including arthritis, asthma, psoriasis, and many bowel diseases (http://ibn.fm/aF04C). 180 Life Sciences is devoting its clinical-stage biotechnology research to producing solutions that will help health professionals battle inflammation when the body’s natural processes go awry. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF therapy, which seeks to suppress the immune system by blocking the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases.

KBL Merger Corp. IV (NASDAQ: KBLM), a special purpose acquisition corporation (SPAC), announced that, in connection with its previously detailed merger agreement with 180 Life Sciences, it consummated a bridge financing on June 29, 2020, and submitted its latest S4 filing with the SEC on August 28, 2020. It expects to close the business combination in Q4 2020. Following the merger, the company will be listed on the Nasdaq Capital Market under ticker symbol ‘ATNF’.

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University.

KBLM has valued 180 Life Sciences at $175 million, with the acquisition being carried out via a share swap through which each share of 180 Life Sciences will be exchanged for one share of KBLM.

Drug Development Programs

180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies.

The company’s primary platform is a novel program to treat fibrosis and inflammation using anti-TNF, with its lead program in phase 2b/3 clinical trials with first results expected in 2021. Further clinical trials are scheduled to begin by the end of 2020. The company has two additional programs that are in the preclinical stage and are showing promising results.

  • Fibrosis & Anti-TNF (Phase 2b/3 Trials): Based at the Kennedy Institute within Oxford University, the fibrosis and anti-TNF program is being led by Professor Jagdeep Nanchahal, a surgeon-scientist who has been running the phase 2 trials, and Professor Sir Marc Feldmann, a renowned immunologist and one of the pioneers of anti-TNF therapy. The program is designed to address four critical areas of inflammation:
    1. The phase 2b/3 trial evaluating the treatment of early stage Dupuytren’s disease (DD) is a fully grant-funded and enrolled study, with top line data expected to be available by Q4 2021.
    2. The phase 2b trial studying the treatment of frozen shoulder is likewise grant-funded and is scheduled to be initiated by Q3 2021.
    3. The phase 2 trial in post-operative cognitive deficit (POCD) is anticipated to commence in Q4 2021.
    4. Preclinical studies in liver fibrosis and nonalcoholic steatohepatitis (NASH) are set to begin in late 2020.
  • Inflammatory Pain (Preclinical): Directed by Professor Raphael Mechoulam at the Hebrew University in Israel, this program is focused on discovering novel compounds to treat chronic inflammatory pain.
  • A7nAChR (Preclinical): Led by Professor Lawrence Steinman and Dr. Jonathan Rothbard, 180 Life Sciences is seeking to develop a treatment for ulcerative colitis in ex-smokers by targeting the a7nAChR, a nicotine receptor in the body and a central factor in the body’s method of controlling inflammation.

Market Size for Anti-Inflammatory Medication

According to a study carried out by Allied Market Research, the anti-inflammatory therapeutics market is expected to grow to an approximate $106.1 billion annual market size in 2020, registering a CAGR of 5.9% during the period from 2015 to 2020.

Ranging from asthma treatments to targeting the causes of diseases such as arthritis, multiple sclerosis, psoriasis and inflammatory bowel disease, anti-inflammatory therapeutics have seen a sharp increase in usage, particularly given that they allow for medical responses that are more targeted and effective while possessing lesser side effects relative to conventional drugs.

Management Team

Professor Sir Marc Feldmann, Co-Chairman, is known to be a pioneer of anti-TNF therapy, which seeks to suppress the immune system by blocking the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases. As of today, anti-TNF therapy drugs have become the world’s largest drug class, with sales estimated at over $40 billion per annum. Feldmann has received seven international awards for biomedical innovation over the years, including the Crawford and Lasker awards, and he is a member of the Royal Society.

Professor Lawrence Steinman, Co-Chairman, is a scientific luminary, having discovered the role of integrins, which led to the creation of Natalizumab, a highlight effective treatment for multiple sclerosis and inflammatory bowel disease. Steinman is a member of the National Academy of Sciences and has received four international awards for biomedical innovation, including the Charcot Prize. Prior to joining 180 Life Sciences, Steinman founded Centocor, a pharmaceutical company that was sold to Johnson & Johnson for $4.9 billion.

Dr. James N. Woody, CEO, was instrumental in the discovery of Remicade as Chief Scientific Officer at Centocor. Previously, Woody founded Avidia and Proteolix, both of which were subsequently sold to Amgen, and he was a General Partner at Latterell Venture Partners. Boasting over 25 years of pharmaceutical research and management experience, Woody was also previously the general manager of Roche Biosciences, the former Syntex Pharmaceutical Company.

Investment Considerations

  • 180 Life Sciences boasts a world-class team responsible for developing new classes of drugs targeting multiple disease states while creating significant shareholder value.
  • The company has a large and expanding patent portfolio.
  • The risks associated with the company’s drug development efforts are mitigated through the concurrent advancement of multiple programs in different stages of development.
  • 180 Life Sciences decreases costs and expedites time to market through the use of grant funding, cost-effective international trials and recruitment of hospital-based luminaries who attract teams of excellence.

Recent News

chart

Kingman Minerals Ltd. (TSXV: KGS)

The QualityStocks Daily Newsletter would like to spotlight Kingman Minerals Ltd. (TSXV: KGS).

Kingman Minerals Ltd. (TSX.V: KGS) was featured today in a publication from MiningNewsWire, examining how NASA recently announced that it is scouting for private companies that would like to go to the moon, collect rocks and dust from the surface and bring them back to Earth. The space agency plans on buying the moon samples for amounts between $15,000-$25,000 for 50 to 500 grams. Jim Bridenstine, NASA’s administrator, announced last Thursday that the collection of moon material would be a part of a technology development program to help astronauts ‘live off the land’ for crewed space flights to the moon or another place in the future.

Kingman Minerals Ltd. (TSXV: KGS), formerly Astorius Resources Ltd., is engaged in the acquisition, exploration and development of gold and silver properties in North America. The Canada-based company is focused on sourcing and developing high-quality properties in favorable mining locations to advance its diverse portfolio of low-cost, lifelong assets.

Kingman Mine

The Company maintains the following projects:

The Mohave Project: Located in the Music Mountains in Mohave County, Arizona. Approximately 35 miles from the town of Kingman, the property consists of 20 lode claims, including the historic Rosebud Mine. The Company has entered into an option agreement to earn 100% over four years. According to historic mappings of the mine, probable ore is 15,560 tons. Possible (inferred) ore is comprised of 176,000 tons, and additional possible (inferred) ore totals slightly over 1,100,000 tons. The total contained gold ounces for all categories is estimated at 664,000 ounces, and contained silver is estimated at 2,600,000 ounces. The Company has recently completed two underground reconnaissance and sampling programs and is in the process of verifying previous resource estimates.

 

The Cadillac East Property: Located approximately 55 kilometers east of Val d’Or, a hub for exploration and mining activities in the Canadian province of Quebec. The Company acquired a 100% interest in the property from an arm’s length vendor. Cadillac East Property consists of 12 claims, and the Company has an option agreement to earn 100% over three years. Having been the subject of numerous geophysical and geological surveys, the Cadillac East Property has been explored and surveyed by numerous companies as well as by the Quebec government. Exploration work done in 2017 by Exploration Facilitation Unlimited Inc. revealed multiple potential targets for future investigation, as results from the soil program identified value in gold, silver, copper, zinc and nickel.

Kingman Minerals is focused on enhancing shareholder value as it continues exploring potential assets and acquiring strategic gold targets. The company recently commissioned mining consulting services company Burgex Mining Consultants Inc. to complete two underground gold exploration programs in the historic Rosebud Mine. Burgex specializes in mineral exploration, mining claim staking, landman services, mining consulting, and the access and documentation of abandoned mine sites throughout the western United States and the world. Burgex’s founders have been active in the industry since 2007 and have identified, secured and consulted on hundreds of thousands of acres of mineral properties spanning a wide range of mineral commodities with billions of dollars’ worth of resources and reserves. The Burgex team has been featured in Forbes Magazine as well as on the Discovery Channel and other outlets. Burgex is at the vanguard of industry advancements in safely accessing difficult vertical abandoned mine workings and continues to pioneer new mineral exploration methods with strategic partners throughout the United States and the world.

Gold’s Predicted Rise

The value of gold is currently on an upward climb due to COVID-19’s upending of the global economy, causing governments to expand their balance sheets. In 2019, as a result of the housing and financial crisis, gold saw its best performance since 2010 — increasing as much as 20% and hitting a top price of $1,549 per ounce in September of that year. Analysts predict its price will continue to climb due to strong buying by central banks, a weakening of the U.S. dollar, and increasing political tensions. A recent Wolfe Research report predicted gold would hit an all-time high, referencing an ounce of gold that commanded a $1,515 asking price. As the value of the U.S. dollar weakens, the demand for gold is inversely rising. Known as a safe-haven asset, gold tends to see increased levels of demand during times of consumer fear or recession.

Management

Sandy MacDougall – Chairman and Director
An economics graduate from the University of British Columbia, Sandy MacDougall brings 30+ years of experience in the investment banking and finance industry to KGS. He was instrumental in the acquisition, development and production of gold at the Alto el Toro mine near Ibaguel, Columbia. As a former investment advisor at Canaccord Capital Corp., MacDougall was a key player in multiple significant financings in Canada as well as abroad, working with a wide range of companies. His experience has afforded him critical exposure to precious and base metal projects throughout North and South America, and he has served as chairman of the board since 2016.

Arthur Brown – President and Director
With 36 years of business experience and service to the boards of eight other companies in sectors ranging from technology to oil, gas and mineral exploration, Arthur Brown adds substantial knowledge in corporate structure and development as well as financings and venture capital to the KGS team.

Cyrus Driver – Independent Director
Cyrus Driver was a founding partner in the firm of Driver Anderson from its inception in 1982 and is a chartered accountant as well as a retired partner in the firm of Davidson and Company LLP. Aside from providing general public accounting services to a diverse range of clients, his specialty is servicing TSX Venture-listed companies and members of the brokerage community. With expert knowledge of the securities industry and its regulations, Driver lends valuable advice to his clients regarding finance, taxation and other accounting-related matters. He currently serves as director and chief financial officer of several TSX-V-listed companies.

Dr. Peter Born – Director and Technical Specialist
A professional geologist registered with the Association of Professional Geoscientists of Ontario and a fellow of the Geological Association of Canada, Dr. Peter Born brings 30+ years of experience in exploration and mining to the company. With prior roles as a senior geologist with Western Mining Corporation, he is currently working with RPS Energy Canada Ltd. on natural gas plays related to high-temperature dolomites and sedimentary zinc deposits (MVT) within the Appalachian Basin in the United States. Dr. Born holds a Ph.D. in earth sciences and has expertise in Precambrian sedimentary geology, basin analysis, sedimentology, stratigraphy and sedimentary ore deposits.

Kingman Minerals Ltd. (TSXV: KGS), closed Wednesday's trading session at $0.10, even for the day, on 177,000 volume. The average volume for the last 3 months is 100,676 and the stock's 52-week low/high is $0.07/$0.23.

Recent News

Kaival Brands Innovations Group Inc. (OTCQB: KAVL)

The QualityStocks Daily Newsletter would like to spotlight Kaival Brands Innovations Group Inc. (OTCQB: KAVL).

NetworkNewsWire Editorial Coverage: With the global e-cigarette and vape market expected to exceed $59 billion by 2027, the vaping industry appears to have weathered a cloud of scrutiny and is emerging better regulated and even stronger. Much of that growth stems from an increasing awareness of the advantages of consuming smokeless and ashless nicotine, backed up with growing studies. Although larger tobacco companies control a large share of the global e-cigarette and vape market, smaller elite players such as Kaival Brands Innovations Group Inc. (OTCQB: KAVL) (KAVL Profile) are making their presence felt in a space where innovation and compliance are essential factors for success.

Kaival Brands Innovations Group Inc. (OTCQB: KAVL) is focused on growing and incubating innovative and profitable products into mature, dominant brands. It aims to develop internally, acquire or exclusively distribute these products, helping them grow into market-share leaders by providing superior quality that is recognizable in their individual industries.

Formerly known as Quick Start Holdings Inc., the company changed its name to Kaival Brands Innovations Group Inc. (also known as Kaival Brands) in July 2019. Headquartered in Grant, Florida, the company commenced business operations on March 9, 2020.

Bidi™ Stick – Revolutionizing the Vaping Experience

On March 9, 2020, Kaival Brands entered into a partnership with Bidi Vapor LLC. The latter granted Kaival Brands exclusive global distribution rights for the innovative Bidi™ Stick.

Bidi™ Stick is a completely self-contained disposable product that is tamper-proof and recyclable. The innovative product is made from high-quality components and equipped with a long-lasting battery and class A nicotine. Its product engineering also includes a sensitivity control system, along with a proven mechanism designed to help identify and eliminate counterfeit products.

Available in 11 flavors, the Bidi™ Stick offers a premium vaping experience for adult consumers only. From its packaging design to its marketing strategies, Bidi Vapor makes sure that everything is compliant with government regulations.

On March 31, 2020, Kaival Brands partnered with QuikfillRx Digital as a digital service provider to help promote and commercialize the Bidi™ Stick. As a direct result of the partnership, Kaival Brands received back-to-back orders for the vaping device, totaling approximately $135,000, from sizable national convenience chains.

On September 8, 2020, the company announced that Bidi Vapor had submitted its Premarket Tobacco Product application (PMTA) to the U.S. Food and Drug Administration (FDA) for review. In total, over 285,000 pages of research, studies and surveys were submitted to support the application of Bidi™ Stick’s 11 variants.

“We are confident that, upon review, the FDA will authorize Bidi Vapor’s Bidi™ Stick for continued marketing in the United States,” Niraj Patel, President and CEO of Kaival Brands, stated in a news release (http://nnw.fm/unAyG).

Bidi Vapor is an industry leader in recycling – a position that was furthered through the creation of the Bidi Cares Initiative. The program encourages users to recycle their used Bidi™ Sticks instead of trashing them. As motivation, Bidi Vapor offers a free Bidi™ Stick for every 10 used devices recycled by a consumer. Kaival Brands is the exclusive recycling provider for the initiative.

Partnership Impact and Market Outlook

Bidi Vapor is a related party to Kaival Brands, as it is owned by Kaival Brands CEO Nirajkumar Patel. Patel is also the majority stockholder of Kaival Brands, placing both entities under common control.

The partnership has already had a positive impact on Kaival Brands, helping the company expedite growth, as evidenced by its Q2 financial results. According to Kaival Brands’ consolidated fiscal results for the quarter that ended on April 30, 2020, its revenues grew to approximately $22.5 million from no revenue in the same quarter of 2019. The company also scored a gross profit of $4.2 million for the three-month period. Net income was reported at $2.8 million for the quarter, compared to a net loss of about $4,000 in the second quarter of 2019. The company ended the second quarter of 2020 with a cash balance of $2 million (http://nnw.fm/44sq4).

The positive results are primarily an effect of Bidi™ Stick distribution amid the growing worldwide demand for high-quality vape products, as Patel explained in a news release. “Our focus now is to continue to increase revenues by increasing Bidi Vapor’s market share in the vaping industry,” he added.

Internationally, Kaival Brands has already taken steps to expand distribution of the Bidi™ Stick into Guam, Canada, the European Union, the United Kingdom, Australia and New Zealand.

To this end, the company has set up a market engagement and sales force to reach a higher volume of retail and wholesale customers. It also created a dedicated customer support team to provide high-quality service and an enhanced customer experience.

Kaival Brands is dedicated to developing innovative and viable options for adults who use tobacco and vape products and want a premium experience. The company wants to set higher standards to transform perceptions and elevate consumer experience in the vape and CBD industries, with a goal of increasing market share in the ever-growing vaping industry. In 2019, the reported global market for the vaping industry alone was $12.4 billion. These forecasts indicate a potential CAGR of 23.8% through 2027.

Cancellation of 300 Million Shares of Common Stock

In August 2020, the company canceled 300 million shares of common stock, marking a 52.1 percent reduction in its issued and outstanding shares of common stock (http://nnw.fm/W7s9T). Currently, the company’s outstanding common shares total 277,282,630. The cancelation was done in exchange for three million shares of Series A Preferred Stock. The Series A Preferred Stock cannot be converted before November 2023, barring any event that may trigger early conversion.

According to Patel, this move will benefit all shareholders and help maintain stability of the market pricing of remaining common stock. The overall goal is to increase value for long-term investors.

Management Team

Nirajkumar Patel is the CEO, CFO, President, Treasurer and Director of Kaival Brands and owner of Bidi Vapor LLC. In 2004, Patel received a Bachelor of Science in pharmaceutical sciences from AISSMS College of Pharmacy in Prune, India. He moved to the United States in 2005, and he continued his education at the Florida Institute of Technology, where he graduated in 2009 with a master’s degree in medicinal and pharmaceutical chemistry. He currently holds a Six Sigma Black Belt Certification.

Eric Mosser is the COO, Secretary and Director of Kaival Brands. Mosser attended Arizona State University, where he studied business management. In 2004, he graduated from Rio Salado College with an associate degree in applied science in computer technology.

Kaival Brands Innovations Group Inc. (OTCQB: KAVL), closed Wednesday's trading session at $0.5295, off by 7.1053%, on 196,055 volume with 80 trades. The average volume for the last 3 months is 209,734 and the stock's 52-week low/high is $0.006/$1.09000003.

Recent News

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF)

The QualityStocks Daily Newsletter would like to spotlight GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF).

GoldHaven Resources (CSE: GOH) (OTCQB: ATUMF) is positioning for opportunity as gold prices continue a remarkable run, in 2020 breaking above $2,000 per ounce for the first time on record. The company has recently announced acquisition agreements for multiple gold projects in Chile, including several advanced projects and assets located in the country’s prolific mining area known as the Maricunga Gold Belt. To view the full article, visit http://ibn.fm/ktXHz

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) (formerly Altum Resources Corp.), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, recently announced its entry into agreements to acquire seven advanced gold projects in the Maricunga Gold Belt of Chile that hosts over 100 million ounces of gold within the last 10 years.

Chilean Gold Properties Being Acquired

On April 17, 2020, GoldHaven Resources entered into an agreement to purchase a 100% interest in two gold projects located in the Maricunga Gold Belt of Northern Chile. The first property, Rio Loa, is located 25 kilometers south of Gold Fields Ltd.’s Salares Norte, where, this year, a five-million-ounce discovery was made. The second property, Coya, is located only 10 kilometers east of the Kinross La Coipa open pit mine, which has produced over 7.5 million ounces of gold to date.

Rio Loa Project

Initial geophysical studies of the Rio Loa site have exposed highly anomalous ardennite and lead values, a key characteristic of gold mineralization within silicified resistive bodies. The studies have also produced initial findings which are similar to those seen at contiguous mines, such as Salares Norte (operated by Gold Fields), which has over five million ounces in estimated gold deposits.

The potential economics for the site look particularly promising when taking the unit costs at the neighboring Salares Norte mine into account. Gold Fields has estimated that its production AISC (all-in sustainable costs) will approximate $552 per ounce and have forecast a 2.3-year payback period for its initial investment, assuming a $1,300 per ounce gold price.

Coya Project

The Coya site is located within close proximity to one of the richest and largest epithermal gold and silver districts in Chile and is in close proximity to active mining sites, specifically the La Coipa mine owned by Kinross. A study carried out in 2017-2018 on the Coya site of 796 rock chip samples found favorable gold and silver values, in some cases ranking as high as 764 grams/tonne of gold and 719 grams/tonne of silver – values which are near certain indicators of potential gold and silver deposits. The La Coipa mine (Kinross) has produced over 6.9 million ounces of gold to date.

On August 11, 2020, GoldHaven Resources acquired five potential gold projects in the Maricunga Gold Belt of Northern Chile. The Maricunga hosts discoveries within the last 10 years of over 100 million ounces of gold and over 450 million ounces of silver. These newly acquired properties are in close proximity to seven other mines, which possess an estimated aggregate of 81 million ounces of gold in total reserves.

GoldHaven’s five new projects cover a total area of approximately 22,600 hectares, or 226 square kilometers, located in the northern portion of the Maricunga Belt in proximity to the 5 million-ounce gold equivalent Salares Norte project owned by Gold Fields. Gold Fields announced in April 2020 its intention to proceed with the development of Salares Norte at a cost of $860 million, with a $138 million expenditure budgeted for 2020.

The Maricunga Belt extends approximately 150 kilometers north-south and 30 kilometers east-west, straddling the border between Chile and Argentina. This region hosts known mineral resources of more than 100 million ounces of gold, 450 million ounces of silver and 1.3 billion pounds of copper.

The Maricunga project’s opportunity came about as a result of a $150 million initiative launched by the Chilean Economic Development Agency (“CORFO”), with the objective of encouraging exploration and mining prosperity in Chile and strengthening Chile’s position as a world leader in the sector.

As part of CORFO’s program, a total of $15.3 million was given to private equity fund IMT Exploration to evaluate 403 projects, beginning in 2011. This led to a generative program carried out from 2016 to 2019, resulting in 126 potential epithermal targets from which 57 field evaluations were made. Due diligence work followed on 19 of these. Work programs were then conducted, including geological mapping, rock and soil sampling and TerraSpec (PIMA) analyses on geochemical grids for alteration mapping, and, as a result, the five high-priority Maricunga projects were identified. No drilling has been carried out on any of the Maricunga projects.

Securing Financing for Upcoming Operations

In conjunction with its announcement regarding its acquisition of five Chilean mining interests, GoldHaven Resources also detailed plans for a non-brokered private placement of 11.5 million units at a price of $0.35 per unit, for gross proceeds of $4,025,000. Each unit will consist of one share of the company and one warrant, the latter of which can be exercised to acquire an additional share of the company for a period of 18 months from the date of issuance at a price of $0.50 per share. Net proceeds from the offering are intended to be used to fund general expenses, as well as exploration and drilling of its mineral properties.

Gold Prices Hit Record High in 2020

Gold prices have been on a remarkable run in 2020, breaking above $2,000 per ounce for the first time on record. Having begun the year at $1,515 per ounce, the precious metal has seen a huge surge on the back of widespread economic uncertainty stemming from governments’ worldwide propensity to expand the money supply, from the reduction of the value of the U.S. dollar as expressed by the decrease in the U.S. dollar index, and from the very real economic effects of the COVID-19 pandemic.

Global central banks have carried out 144 interest rate cuts thus far in 2020, reducing rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures has prompted a number of investment banks to boost their near-term outlooks for gold prices, with Bank of America raising its 18-month gold price target to $3,000 per ounce (http://nnw.fm/PQJtc).

Leadership Team

David Smith, President, CEO and Director, has been immersed in the mining industry for the last eight years, working in corporate development and finance. Prior to GoldHaven Resources, Smith cofounded a multifaceted real estate development and sales company, which has now been in operation for over 35 years. He also cofounded two successful environment-focused companies listed on the Toronto Stock Exchange. Both companies were sold independently and returned a significant profit for shareholders.

Darryl Jones, Chief Financial Officer, is a finance executive and CPA with over 30 years of public company and project buildout experience. Most recently, Jones served as the CFO of Lupaka Gold Corp., retiring in June 2018. Prior to that, Jones serves as CFO of Corriente Resources, which was sold to CRCC-Tongguan in May 2010 for C$680 million.

Patrick Burns, VP Exploration and Director, is a Canadian geologist with over 40 years of experience throughout the Caribbean and Central and South America. He played a direct role in the discovery of the Escondida porphyry copper deposit in Chile and has been involved in publicly traded mining companies, predominantly in Chile, for 35 years.

Marla Ritchie, Corporate Secretary, brings over 25 years of experience in public markets to the GoldHaven team. Throughout this time, she has worked as an administrator and corporate secretary specializing in resource-based exploration companies. Currently, Ritchie is the corporate secretary for several companies, including International Tower Hill Mines Ltd. and Trevali Mining Corp.

Gordon Ellis, Director; has over 50 years’ experience in mining and resource development. A professional engineer and entrepreneur, he has held multiple senior management and director roles with public mining companies, as well as a multi-billion-dollar ETF fund. Ellis holds an MBA in international finance and a Chartered Directors designation.

Scott Dunbar, Director is a professor and head of multiple departments at the University of British Columbia, including mineral extraction and mining innovation, as well as mining engineering. He has been involved in projects around the world in regard to mining exploration, geotechnical engineering and mine design. Dunbar received his PhD in geophysics and civil engineering from Stanford University.

GoldHaven Resources Corp. (OTCQB: ATUMF), closed Wednesday's trading session at $0.34, off by 0.17616%, on 13,381 volume with 4 trades. The stock's 52-week low/high is $0.109999999/$0.446000009.

Recent News

Pac Roots Cannabis Corp. (CSE: PACR)

The QualityStocks Daily Newsletter would like to spotlight Pac Roots Cannabis Corp. (PACR).

Pac Roots Cannabis Corp. (CSE: PACR) was featured today in the 420 with CNW by CannabisNewsWire. The harvest season is the most taxing as well as the most thrilling time of the outdoor plant growth cycle. This season can either make or break an entire year’s operation. To ensure your harvest is snag-free and also successful, here are some of the key things you should make sure are ticked off your ‘before-harvest’ checklist.

Pac Roots Cannabis Corp. (CSE: PACR) is a Canadian cannabis company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach.

The company began operations in 2012, with activities primarily directed toward exploration and development of mineral properties in Canada. Today, it is focused on cannabis and hemp cultivation, leveraging high-end genetics and specialized cultivars to produce top quality products. Pac Roots has announced multiple promising initiatives in recent months, including its formation of an outdoor premium hemp joint venture with partner Rock Creek Farms in British Columbia, Canada, and its agreement to acquire all issued and outstanding shares of a firm holding 250 acres of land in the famed Fraser Valley Region of British Columbia.

Pac Roots is also in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through an elite line of 350+ unique, high-grade cultivars. Pac Roots expects to receive a cultivation license for the facility in the fourth quarter of 2020.

High-End Selectively Bred Genetics

Pac Roots focuses on high-end genetics in order to maximize the quality of its products while maintaining high yields and profit margins.

Through the process of artificial selection, farmers and cultivators have been adapting their plants to develop particular phenotypic traits for generations. Historically, this practice was restricted to underground cannabis producers developing their own strains.

The legalization of the cannabis industry has given producers access to thousands of cultivars located throughout the world while accelerating research into cannabis genetics. By carefully selecting strains, growers can control the size, color, smell, density and texture of cannabis buds, thereby creating distinctive, premium cannabis products.

Plants are bred to thrive in specific growing environments. This maximizes the yield of high-quality, resilient cannabis. Medical cannabis strains can also be tailored for specific medicinal purposes.

A strategic partnership with Phenome One, a plant breeding management and analytics firm, gives Pac Roots access to some of the world’s best cannabis genetics from the largest genetic library in Canada. The company is using these genetics to develop unique strains featuring a variety of beneficial characteristics.

The company’s 350+ licensed live cultivars and over 1,800 seed varieties are the result of a meticulous gene selection process, through which as many as 600 individual plants may be grown to produce a single strain. Selecting optimized genetics in this way provides benefits beyond simply producing a high-end product. In addition to potency and bud quality, cannabis plants are bred for yield and resilience. By selecting genetics that result in larger and more numerous buds on each plant, Pac Roots is able to grow more cannabis per grow light.

Breeding plants to be more resilient also reduces the cost and labor required. These factors, combined with the premium price point associated with top-quality cannabis, have the potential to improve Pac Roots’ overall profit margin.

Partnership with Phenome One

Pac Roots has secured its cultivars through a strategic licensing agreement with Phenome One. Under the agreement, Pac Roots has unlimited access to Phenome One’s live genetic library, including any of Phenome One’s cultivars and its growing, breeding and cloning IP.

Phenome One is an agricultural technology company focused on providing software solutions to seed companies. Phenome One’s platform gives its partners access to a massive database of detailed information on over 350 unique cannabis cultivars to support each stage of the breeding process. Each cultivar has been laboratory analyzed and rigorously field-tested, with data going back more than 30 years.

Using Phenome One’s data, Pac Roots plans to grow a variety of cannabis plants optimized for certain traits. One such trait will be plants with an abundance of cannaflavin, a rare terpene with high anti-inflammatory properties. Phenome One’s library could enable Pac Roots to produce plants that are bred to thrive in a range of different growing climates, including plants suited to grow in cold weather and plants that are resilient to region-specific fungi.

Joint Venture with Rock Creek Farms of British Columbia

Pac Roots recently entered a definitive investment agreement with Rock Creek Farms, a reputable agricultural enterprise, for a 100-acre commercial hemp operation in Rock Creek, British Columbia. The growing space is located in the highly lucrative farming area known as the ‘Golden Mile’ in the South Okanagan Valley of British Columbia. (http://nnw.fm/Gbf9I).

Under the agreement, the two companies have formed an outdoor premium hemp joint venture company to which Pac Roots is providing an aggregate of $450,000 in capital and Rock Creek Farms is contributing two commercial leases for 100+ acres of growing space, along with cultivation licenses, agricultural infrastructure and equipment, consulting services, intellectual property relating to hemp operations and proprietary biomass storage methods. Pac Roots holds a 60 percent interest in the project.

About 127,500 premium hemp CBD seedlings were planted across 100 acres as of early July 2020. The joint venture is planting a premium grade CBD hemp variety utilizing the rich native soil and both traditional and custom farming techniques.

“Our operational partners at Rock Creek Farms bring decades of generational farming expertise in one of Canada’s pre-eminent growing regions,” Pac Roots President and CEO Patrick Elliott said in a news release detailing the venture. “It will be an exciting outdoor growing season for the joint venture as we anticipate a successful harvest in the fall.”

Infinite Development Possibilities at Fraser Valley Property in British Columbia

In mid-July 2020, the company initiated a share purchase agreement with 1088070 BC. LTD. (“1088”) and its shareholders for the acquisition of all issued and outstanding shares of 1088 (http://nnw.fm/xlpw7). Notably, 1088 owns and controls 250 acres of land spread over nine parcels in the Fraser Valley Regional District.

The Fraser Valley Regional District is one of the most productive and intensively farmed areas of Canada, offering access to high-quality soil, favorable climate, water and a local market of 2.5 million people. Agriculture in this region yields an annual economic value of more than $3 billion.

The closing date for the transaction is slated for September 4, 2020, after a 51-day due diligence period. According to Elliott, the addition of such a significant package of land is a major step for Pac Roots.

“This land has no zoning restrictions and is not situated within the agricultural land reserve, which provides for infinite development possibilities,” Elliott added in a July 2020 news release.

Board of Directors member Chad Clelland also welcomed the acquisition, adding that between Fraser Valley and Rock Creek – both of them among the most productive agricultural regions in Canada – Pac Roots is very well positioned for production and the future development of its hemp and cannabis infrastructure.

The RAD Americas Genetic Program – Research and Development in Americas Genetic Program

Pac Roots intends to deploy a global R&D program focused on rigorously testing elite strains in various rich agricultural regions throughout the Americas, with a goal of mass selection to achieve the utmost environmental resilience while achieving notable quality and yields. From seed to software, collection data, proprietary techniques and custom nutrient formulas, Pac Roots and Phenome will provide the specific knowledge to cultivators in different climates in order to achieve optimal yields for THC, CBD, CBG and other unique cannabinoids. R&D from global testing programs situated throughout the Americas will allow the partnership to deploy and stress test a range of suitable cultivars in the world’s lowest cost outdoor growing regions.

The company expects an industry shift in 2020 from the COVID-19 global pandemic. The ‘new normal’ will bring more focus on efficiencies and optimal yields to deliver a cost effective, high quality product to the end user. There has been much to be learnt from the inefficiencies in the cannabis industry in recent years, which have been detrimental to the credibility of the sector. Pac Roots is well positioned to enter the scene and take advantage of the deficiencies, reinforcing the notion that genetics and flawless growing techniques are paramount to success. Genetics and systems innovation may be the most overlooked components when comparing cannabis to other established agricultural crops. Pac Roots plans to invest into cannabis R&D to ensure a solid foundation is built that will be used by cannabis farmers worldwide.

Through its RAD Americas Development and Innovation, Pac Roots is focused on:

  • Deploying one of the largest live genetic libraries in Canada, diversified for high yield output and unique climates
  • Continued stress testing for indoor, high yield, THC and medicinal genetics
  • Continued stress testing for outdoor, high yield, THC and medicinal genetics
  • Exotic, genetic cloning for the luxury, high margin, cannabis flower market
  • Psychoactive/medicinal ratio testing for effect and
  • Unique Cannabinoid and terpene elevation and isolation.

Through its RAD Americas Field Testing System, the company is focused on:

  • Global testing in different microclimates to assess genetic and complete systems for optimal yields
  • Data collection, testing and optimization to prove process for commercial implementation and
  • High quality yield testing for THC, CBD, CBG and other unique medicinal cannabinoids.

Lake Country Cultivation Facility near Kelowna, British Columbia

Pac Roots is in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through its line of high-grade cultivars. Pac Roots plans to submit a video evidence package of the facility build under Health Canada’s Cannabis Tracking and Licensing System, and the company expects to acquire its cultivation license in the fourth quarter of 2020.

Lake Country is a municipality located just outside of Kelowna in the Okanagan region of British Columbia. For decades, the region’s favorable growing climate has made it a hub for cannabis cultivation. As the Canadian legal cannabis industry ramps up, the Okanagan region is attracting attention from dozens of cannabis companies, including some of the industry’s biggest names. The region’s strong agricultural history has left it rich with experienced agricultural workers and an abundance of Agricultural Land Reserve (ALR) property.

Management Team

Patrick Elliott, MSC, MBA, President and CEO of Pac Roots Cannabis, is also the President & CEO of Lexore Capital Corp., a private resource and cannabis investment company, as well as Phenome One Corp., a full-service cannabis farming company focused on elite strain selective breeding. Elliott brings over 15 years of corporate finance, mineral exploration and financial markets experience to the Pac Roots team. He is a graduate of the University of Western Ontario in geology and holds an MSc. in mineral economics and an MBA from Curtin University of Technology in Perth, Australia. Elliott specializes in economic resource evaluation, financial modeling, CAPEX estimation, corporate development and finance. Combined with his technical knowledge, Elliott has a wealth of contacts in the financial sector.

Marc Geen, Founder and Strategic Operations Advisor, is a fourth-generation British Columbia farmer who has been active in the legal medical marijuana industry for more than 10 years – consulting on, complying with, and participating in the MMAR, MMPR and ACMPR programs. Prior to co-founding Speakeasy Cannabis Club Ltd., Geen spent 14 years as Head of Operations for Kettle Mountain Ginseng Ltd., one of North America’s largest ginseng producers. With the experience gleaned from a long career in large scale commercial farming, Geen has been able to apply many cost-effective farming practices to the outdoor, indoor and greenhouse cultivation of cannabis. Geen is also the co-creator of a full line of cannabis extract products designed under ACMPR regulations.

Matt McGill, Director, has a strong background in both commercial and residential real estate and has played a major role in many development projects. McGill, through McGill Realty, has established a tremendous commercial and residential outfit servicing British Columbia’s Fraser Valley and the lower mainland. McGill is skilled at crafting strategic financing options for corporations and has a substantial network of retail and institutional clients.

Chad Clelland, Director, has experience in the sector dating back to 2009, when he purchased Medicalmarijuana.ca, which became an information portal for thousands of patients, doctors and growers. Through this company, he and his team have helped thousands of Canadians find legal, safe medication. His team also consulted, designed and submitted dozens of applications to the government under the MMPR, ACMPR and Cannabis Act. In 2011, Clelland co-founded Greenleaf Medical Clinic, which is now recognized as a training facility by the University of British Columbia and offers preceptorships to physicians, nurse practitioners and pharmacists. He also co-founded Folium Life Science in 2013, an approved Canadian Licensed Producer. His roles in these organizations have included Chief Operating Officer, head of security, alternate master grower and alternate responsible person in charge.

Josh Bromley, Senior Cultivation Strategist, is a second-generation farmer with over two decades of experience farming, breeding, cultivating and selecting unique cultivars for the medical community. He is an expert in plant science and possesses a comprehensive knowledge of cultivars and a mastery of medicinal implementation. Bromley has developed proprietary farming systems, as well as low cost/high output nutrient systems. Through thoughtful design and engineering, he has been able to consistently show improvements in crop yields, pathogen resiliency and quality.

Pac Roots Cannabis Corp. (PACR), closed Wednesday's trading session at $0.215, off by 8.51%, on 11,500 volume with 2 trades. The average volume for the last 3 months is 21,245 and the stock's 52-week low/high is $0.11/$0.72.

Recent News

InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: IGSTF)

The QualityStocks Daily Newsletter would like to spotlight InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: IGSTF).

InsuraGuest Technologies (TSX.V: ISGI) (OTC: IGSTF), an innovative insurtech leader, has announced a premier preferred partnership with Hub International, a leading global insurance brokerage, to lower insurance premiums and transfer risks for hotel clients. According to the agreement, InsuraGuest will provide its exclusive Hospitality Liability coverage to HUB hotel clients in the United States with plans to expand to HUB's clients in Canada by mid-2021. To view the full press release, visit http://nnw.fm/OfDRW

InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: IGSTF) is a leading global SaaS (Software-as-a-Service) company leveraging its proprietary, flagship insurtech (insurance + technology) software, InsuraGuest, which is integrated with the property management systems of hotels and vacation rentals to deliver custom Hospitality Liability coverages.

InsuraGuest’s Hospitality Liability coverages are purchased by hotels and vacation rental properties, which can address claims from guests and their room occupants. The combination of the integrated software and customized insurance provides the property liability coverages the guests benefit from in the event a loss is incurred during their stay.

The Hospitality Liability policy is offered through integration of InsuraGuest’s API with the clients’ property management systems. InsuraGuest’s platform is currently capable of integrating with approximately 71 different hotel and vacation rental property management systems, giving it access to millions of rooms worldwide.

InsuraGuest continues to pursue expansion opportunities in the United States, and has plans to expand to its distribution platform and Hospitality Liability coverages to the United Kingdom and Europe regions by third quarter 2020, as well as expansion into Asia by the end of 2020.

Protection that Enhances the Guest’s Experience

InsuraGuest’s Hospitality Liability coverages add a layer of protection for the property on a primary basis, should a guest experience an accident or theft while staying at an InsuraGuest member hotel or vacation rental property.

Market Opportunity

The U.S. hotel industry generated more than $218 billion in annual revenues in 2018, an increase of $10 billion from the previous year, according to STR’s 2019 HOST Almanac. The European market is more than double the size of the U.S. market. According to Oxford Economics, there were 6.4 billion nights stayed in the world, with 2.6 billion hotel nights stayed in Asia, 2.8 billion nights stayed in Europe, and 1.1 billion stayed nights in the United States. Additionally, $100 billion was spent on vacation rentals in the United States, where there approximately 4.5 million second homes are being managed by a third-party rental company.

With distribution in Europe and the United States, InsuraGuest’s combined demographics will total 3.9 billion nights stayed, and will more than double its vacation rental opportunities.

Within this burgeoning, high-demand industry is risk of liability to guest injury. For example, gym injuries are among the top five most common hotel accidents. Without proper hedges in place, the property may be liable in a personal injury claim or lawsuit that are not the properties fault.

Though the potential for accidents, slip and falls and mishaps can be widespread, it can be covered under the InsuraGuest Hospitality Liability policy to provide guests a worry-free and enjoyable stay that potentially increases loyalty for the property.

Investment Consideration

  • Targeting hotels and vacation rentals, a multi-billion-dollar industry
  • Providing the first line of defense in case of accident, loss or death
  • Expanding distribution reach with footing in European hotel and vacation rental markets
  • Expansion into Asia by 2020

Executive Team

Douglas Anderson, Chairman & Chief Executive Officer
Douglas Anderson has been a businessman in the real estate industry for nearly 30 years. His business expertise includes master planning and development implementation for larger-scale resorts, business parks and commercial developments across the USA and two provinces in Canada. His business endeavors include the founding of the 7th larger private equity fund in America focusing on multifamily and senior care (ROC Fund/Bridge IPG Fund). He serves as chairman/founder of a golf and winter sports ski holding company with operations in four major east coast markets and British Columbia, Canada.

Anderson earned a Bachelor of Science in consumer studies with an emphasis in architecture as an undergraduate at the University of Utah. He subsequently earned his MBA. He also attended a three-year OPM Program a postgraduate business education at Harvard Business School in Boston. Anderson is an avid skier and outdoor enthusiast.

Logan Anderson, CFO & Director
Logan Anderson (bachelor’s degree in communications, accounting and economics) holds the designation of ACA with the Chartered Accountants of Australia and New Zealand. He began his career as an associate chartered accountant in New Zealand and then Canada. This was followed by his position as controller of a management services company which was responsible for the management of numerous private and publicly traded companies. Since 1993, Anderson has served as president of Amteck Financial Corp. (and its predecessors), a private financial consulting services company servicing both private and public companies. He is a former director of 3D Systems, Inc. (NYSE: DDD), and was formerly a founder, officer, and director of Worldbid.com. Anderson has also been involved in raising funds for numerous private and public companies in all stages of their development and has been an officer and director for numerous public and private companies over the past 40 years.

Charles James Cayias, President & Director
Charles James Cayias is also the president and owner of Charles James Cayias Insurance Inc. He is a third-generation insurance professional whose creativity and artistic vision have enabled him to establish a full-service agency combined with the personal service each client deserves. His outstanding people skills, honesty, integrity and fairness are evident by his loyal and growing clientele, the majority of which are referrals who become long-time customers and friends. Cayias began his insurance career in the early 1970s and has been licensed since 1977. He is licensed in all 50 states and specializes in niche programs. He has extensive expertise in all aspects of the insurance industry including commercial insurance, employee benefits, workers’ compensation, professional liability, risk management and bonding.

Tony Sansone, COO & VP of Finance
Tony Sansone has over 30 years of financial, operations and business development experience which includes serving as CFO in the health care, foodservice distribution, manufacturing and technology sectors, including public company experience. He has held senior finance positions in the banking, telecommunications, medical products, and food & drug retailer industries, closing over $430 million of private debt, equity and line of credit financings and over $350 million of a merger, acquisitions, real estate and state incentive transactions, including due diligence, negotiations, closing, and integration. Sansone coordinated and was the executive sponsor for four ERP implementations and multiple other best-in-class software & technology solutions. He received his MBA from the University of Utah and a Bachelor of Science in accounting from Utah State University. Sansone also currently serves as president-elect of the Utah Chapter of Financial Executives International and a past president and current member of the board of trustees for Catholic Community Services of Utah. He is the proud father of three children.

Christopher J. Panos, Vice President & Director
Christopher J. Panos is a highly competitive sales professional with over 15 years of territory manager sales experience and an award-winning record of achievements. He is exceptionally well organized with a proven work history that demonstrates self-discipline, superb communication skills, and the initiative to achieve both personal and corporate goals. Panos is successful in building relationships with a large network of industry professionals in order to grow and maintain new and existing business, exceed new sales objectives and provide in-depth product training to authorized dealers and sales personnel.

Alexander Walker III ESQ, Corporate Counsel & Director
Alexander Walker III ESQ has served as director of the company since September of 2018 and as counsel to the company since July of 2018. Walker is an attorney and has been a member of the Utah Bar Association since 1987 and a member of the Nevada State Bar since 2003. His practice has involved general business litigation, in both federal and state courts, and transactional work, including securities offerings and registration, corporate formation and periodic reporting compliance. Walker has provided legal services to emerging businesses throughout his carrier and at times has served as an officer and board member as well as legal counsel public companies. His duties as legal counsel for a public company engaged in the business of ownership and operation of coal-producing properties in the western United States included oversight of corporate-related legal matters including securities reporting, corporate compliance, federal and state mining regulation, and employment law oversight. He also has served as the chair of the Mining Committee of the Energy, Natural Resources and Environmental Law Section of the Utah State Bar, a member of the board of directors of the South East Utah Energy Producers Association, the co-chair of the board of the Western Energy Training Center, a board member of the Utah Supreme Court Committee to Review the ABA Recommendations Regarding the Office of Professional Conduct, and a board member of the University of Utah Crimson Club.

Jennifer Epperson, Vice President of Sales
Jennifer Epperson has over 20 years of B2B sales experience with exceptional success history. She has grown and developed sales territories across multiple industries. Her ability to find and develop strategic relationships has given her top-level performance throughout her career. Epperson’s passion and knowledge provide an inherent ability to connect and retain relationships for the growth of the company. Throughout her professional career, she has achieved peak performance sales results and awards year after year. She captures the vision of the company and drives it forward with enthusiasm and expertise. Her commitment to providing an exceptional customer experience has been the key to her success.

Richard Matthews, Interim Financial Controller
Richard Matthews joined the InsuraGuest team in March 2019 as the interim financial controller. Leading the Finance and Audit team, Matthews is responsible for the delivery of financial services such as accounting, treasury, reporting, budgeting and insurance management, in accordance with legislative requirements and organizational policies and strategies. He has over 30 years of experience in providing professional services across a broad range of finance areas including compliance, business process, audit, and financial reporting. He holds a degree in accounting from the University of Utah and is a licensed CPA in the state of Utah.

Roger Bloss, Corporate Consultant & Board Advisor
Roger Bloss joined InsuraGuest in August of 2019 to advise the company and its board on hotel transactions, contributing his knowledge from more than 40 years in the hospitality industry. Bloss previously served in executive positions with several major hotel franchise companies and in 1996 founded Vantage Hospitality Group hotel brands. Under his leadership, Vantage became a Top 10 global hotel company and made the Inc. 500/5000 list of Americas’ fastest-growing private companies for eight straight years. Bloss was named Lodging Magazine’s “Innovator of the Year” in 2006 and 2010, and in 2009 earned a spot on HSMAI’s “Top 25 Extraordinary Minds in Sales and Marketing.” Bloss joined Red Lion Hotels Corporation (RLHC) in September 2016 in conjunction with the acquisition of Vantage.

Jim Kilduff, Board Advisor
James “Jim” C. Kilduff has nearly 40 years of experience in the insurance and risk management sectors. He is a dynamic and energetic team leader and builder with extensive experience in the changes affecting the insurance business through Gas, alternative distribution, insurtechs and program business. His skillset includes experience as chief insurance officer with Outdoorsy Insurance Group, CEO with Harbor Hill Solutions Inc., and senior vice president and chief marketing officer with State National Insurance Companies. His career has spanned MGA creation and management, insurance company management, business development and underwriting, primary insurance and reinsurance.

Don Archibald, Board Advisor
Don Archibald brings to InsuraGuest’s advisory board 54 years of experience as an insurance agent. Archibald is the founder and former owner of Archibald Clarke and Defieux (ACD Insurance), as well as the co-founder and former equity partner of Sussex Insurance, and an agent with Sussex since 2014.

InsuraGuest Technologies, Inc. (OTC: IGSTF), closed Wednesday's trading session at $0.1454, even for the day, on 20,0000 volume. The average volume for the last 3 months is 620 and the stock's 52-week low/high is $0.079300001/$0.248799994.

Recent News

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT)

The QualityStocks Daily Newsletter would like to spotlight Blue Hat Interactive Entertainment Technology (BHAT).

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a leading producer, developer and operator of augmented reality ("AR") interactive entertainment games, toys and educational materials in China, today announced that its subsidiary, Xunpusen Technology Co. Ltd. ("Xun Pu Sen"), generated approximately RMB 10 million (approximately US$1.5 million) in revenue in the first month of its operation. In previous years, Blue Hat had focused on delivering its AR interactive games and toys through traditional "brick and mortar" and e-commerce sales channels. In an effort to seek additional means of engaging with potential customers, the company utilized its recently acquired subsidiary Xun Pu Sen to implement a sales strategy by leveraging its strength in enterprise software solutions and mobile/SMS sales to promote products directly through customers via mobile and desktop. To view the full press release, visit http://nnw.fm/W973i

Blue Hat Interactive Entertainment Technology (BHAT) is a cutting-edge creator, developer and operator of popular augmented reality (“AR”) interactive smart toys and educational games in China. Blue Hat’s mobile-connected entertainment platform connects physical items to mobile devices through wireless technologies, creating a unique interactive user experience in various mobile games, interactive educational materials and toys with mobile game features.

Blue Hat designs original toys and games that utilize augmented reality technology, motion capture technology, image recognition technology, voice control, light sense technology, infrared, levitation induction, and other trending scientific technologies to transverse the virtual with reality. Blue Hat creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. This combination provides users with a more natural form of human computer interaction, enhances a user’s perception of reality, and delivers a more immersive entertainment experience.

Proprietary Technology

Founded in 2010, Blue Hat’s proprietary technology, product research and development, marketing channels and brand operation are the cornerstones of the business. Blue Hat focuses on the combination of “online” and “offline” activity and the interaction between “entertainment” and “product” to create a high-tech entertainment platform combining mobile games and AR. With the help of computer graphics, motion capture technology, image recognition technology and visualization technologies, Blue Hat accurately “places” virtual objects into the physical world, creating a new and stimulating visual environment for users.

Blue Hat recently displayed a variety of its sci-tech products at the Guangzhou International Toy Exhibition in China including AR Racer, Elastic Bubbles, AR Space Track, AR Alloy Toy Car, AR Need a Spanking, 5D Animated Magic Aquarium, Bug Travelers, AR Picture Book and other interactive games and smart toys.

The company has multiple products in development including new generations of four primary product lines and two new product lines.

Patents and Copyrights

Blue Hat’s advanced AR technology in interactive entertainment is protected by 178 authorized patents with 44 patents in various stages of the application process.

Another 14 applications for Patent Cooperation Treaty, or PCT, have been filed for international patents. As of March 31, 2019, the company owns 645 copyrights for artwork, 71 registered trademarks and 27 software copyrights.

Sales and Marketing

There has been rapid growth in the toys and games industry in China over the last several years. Total retail sales of toys and games in China soared from RMB 111.8 billion in 2012 to RMB 276.5 billion in 2017 with an average annual growth rate of 19.9% in 2017. Blue Hat believes the company is well positioned with little competition as the toy industry rapidly shifts toward intelligent and interactive toys and games. Retail sales of electronic toys grew at 24% annually in 2017 while that of traditional toys grew at 7%.

In addition to a powerful ecommerce presence, Blue Hat has long-term relationships with partnered distributors that place the company’s AR interactive entertainment products into well-known international retail chains and retail outlets. Blue Hat’s integrated online and offline sales channels include e-commerce giants such as Amazon and Alibaba, retail chain stores and the company’s physical experience store located in Xiamen, China. Blue Hat plans to open or franchise approximately 100 additional stores in China by 2021.

Blue Hat’s community-based platform offers users a highly engaged and interactive community with online communication forums and offline social activities. The company advocates a new model of “teaching through lively activities” and combines AR technology with education, integrating its products into situational teaching, roleplaying and man-machine interaction. This novel educational experience helps realize optimal transformation of information, creating a knowledge and enhancing cognition.

Management

Director and CEO Xiaodong (Sean) Chen has over 20 years of experience creating, developing and producing toys and games related products. Chen earned his EMBA from Renmin University of China and has been chairman of the board of directors and general manager of Fujian Blue Hat Interactive Entertainment Technology Ltd. since August 2015.

CFO and Director Caifan, who has over 20 years of financial accounting and taxation experience, earned a degree in finance from Hunan University of Finance and Economics. He has served as director, deputy general manager and financial controller of Fujian Blue Hat Interactive Entertainment Technology Ltd. since August 2015.

Jianyong Cai, chief technology officer and director, has over 35 years of experience in data communication principles, communication network foundation, software engineering, communication network theory and technology and computer network architecture. He holds degrees in data communication principles, communication network foundation and software engineering from University of Science and Technology of China. He has been director, deputy general manager and chief engineer of Fujian Blue Hat Interactive Entertainment Technology Ltd. since January 2010.

Blue Hat Interactive Entertainment Technology (BHAT), closed Wednesday's trading session at $1.14, up 5.5556%, on 1,082,451 volume with 1,784 trades. The average volume for the last 3 months is 967,842 and the stock's 52-week low/high is $0.630800008/$3.71000003.

Recent News

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF), a leading producer of premium certified organically grown cannabis, has signed a letter of intent with Quebec-based Chocolatier to produce a new line of premium cannabis-infused, organic chocolate at its Valleyfield site. The new product line, part of TGOD’s strategic plans for expansion, will feature high-quality Belgian chocolate and organic gourmet ingredients. To view the full press release, visit http://cnw.fm/CTLD7. Also today, the company was highlighted in the Investor Ideas Potcast, from Investorideas.com , a global news source covering leading sectors including marijuana and hemp stocks - its potcast site, www.potcasts.ca released today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed Wednesday's trading session at $0.2704, up 6.0392%, on 688,218 volume with 262 trades. The average volume for the last 3 months is 647,942 and the stock's 52-week low/high is $0.150000005/$2.05999994.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.